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ABSTRACT 
 
 
Factors That Influence Follow-up After an Abnormal Mammogram.  (December 2006) 
Valerie Anne Copeland, B.A. Mount Holyoke College; 
M.P.H. University of California, Berkeley 
Chair of Advisory Committee:  Dr. Jeffrey J. Guidry 
 
 
The focus of this study was to explore women’s experiences with follow-up after 
an abnormal mammogram, and factors that influence follow-up.  Factors, including 
health status, found in the cancer screening and treatment literature, are necessary in 
identifying variables which have the potential to affect a person’s perception, and 
promote or deter follow-up.  Protection Motivation Theory constructs utilized in this 
study are found in the literature to improve diagnostic health behaviors such as 
performing breast self-examination and complying with diagnostic tests. 
A non-experimental, descriptive, cross-sectional design was used to identify the 
barriers to follow-up after an abnormal mammogram by: 1) determining the 
noncompliance rate of follow-up mammograms among women screened at an urban 
hospital’s mammography mobile unit in North Texas (October 1, 2004, to September 31, 
2005) who were found to need further evaluation for suspected abnormal findings; and 
2) identifying factors associated with noncompliance and perceived barriers to 
noncompliance. 
The sample consisted of 262 participants, 136 (52%) women whom the hospital 
reported had not returned for follow-up and 126 (48%) women who were reported to 
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have returned.  A logistic regression model was performed using follow-up as the 
dependent variable.  The variables most related to follow-up were (1) number of 
mammograms in the last 5 years; (2) having health insurance; (3) having problems 
receiving abnormal mammogram results; (4) having problems receiving or making a 
follow-up appointment; (5) taking off from work for the follow-up appointment; (6) not 
having transportation to follow-up appointment; and (7) waiting a long time to receive 
the follow-up appointment.   
Non-compliance to recommended follow-up after an abnormal mammogram is a 
serious public health concern, since breast cancer screening can improve breast cancer 
outcomes only if prompt diagnostic resolution and access to state-of-the-art care is 
available to all screening participants.  This study adds to the literature on predictors of 
follow-up after an abnormal mammogram, as well as the to the health disparities 
literature. 
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CHAPTER I 
 
INTRODUCTION 
Overview 
Despite the recent statistics indicating a decrease in breast cancer mortality, 
breast cancer continues to be one of the leading causes of morbidity and mortality 
among women in the United States.  Breast cancer screening aims to detect cancers 
when they are as small as possible and before there is evidence of lymph node 
dissemination.  Few women in a regularly screened population should be diagnosed with 
late-stage cancer because, in theory, screening should identify cancers before they 
progress to later stages.   
Mammography screening is an effective tool for the prevention of breast cancer 
mortality.  Many women have abnormal findings on screening mammograms that 
require follow-up to eliminate the possibility of breast cancer.  A recent review of 
studies on follow-up of abnormal screening examinations reported that, in the majority 
of studies, 75% of patients did not receive adequate follow-up care (Bastani et al., 2004).  
When an abnormality is detected on screening mammography, clinical evaluation and a 
thorough radiological work-up are needed to determine the significance of the 
abnormality.  Delays in follow-up for abnormal mammograms potentially can lead to 
more severe outcomes associated with breast cancer, including later stages of diagnosis 
and subsequent increased mortality.   
________ 
This dissertation follows the style of Evaluation & The Health Professions. 
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Waiting for a definitive diagnosis following an abnormal mammogram is a 
critical element in the breast cancer care process.  Despite the potential seriousness of 
women receiving inadequate or no follow-up after an abnormal mammogram, there has 
been little research on the determinants of follow-up of abnormal mammograms 
(Arnsberger Webber, Fox, Zhang, & Pond, 1996; Barton et al., 2004; Boudreau, 
McNally, Rensing, & Campbell, 2004; Juarbe et al., 2005; Kaplan, Crane, Stewart, & 
Juarez-Reyes, 2004; Kerlikowske, Smith-Bindman, Ljung, & Grady, 2003; Kerlikowske, 
1996; Lipkus, Halabi, Strigo, & Rimer, 2000; McCarthy, Ulcickas Yood, Boohaker, et 
al., 1996; McCarthy, Ulcickas Yood, Janz, et al., 1996; Olivotto et al., 2002; Strzelczyk 
& Dignan, 2002; Taplin, et al., 2004; Thorne, Harris, Hislop, & Vestrup, 1999; Yabroff 
et al., 2004).  This study seeks to identify factors that influence a woman obtaining 
follow-up after an abnormal mammogram. 
Breast Cancer Statistics 
Breast cancer is a leading cause of death among women in the United States and 
is the most common type of cancer in women worldwide.  About 200,000 women are 
diagnosed, and approximately 40,000 deaths are attributed to breast cancer each year.  It 
is the most frequently diagnosed cancer in women.  Breast cancer incidence rates have 
risen in the United States for the past two decades due to increased use of 
mammography; however, in some populations, particularly among racial minorities and 
the poor or medically underserved, the percentage of women with advanced disease at 
diagnosis remains high (American Cancer Society [ACS], 2005a; Jacobellis & Cutter, 
2002; Jones et al., 2005; Juarbe et al., 2005; Kaplan et al., 2004; Kerlikowske et al., 
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2003; Kerner et al., 2003; Olivotto et al., 2002; Strzelczyk & Dignan, 2002; Yabroff et 
al., 2004).   
Although the lifetime chance of developing breast cancer is higher for White 
women than for Black and Hispanic women, Black women and subgroups of Hispanic 
women have a lower breast cancer survival rate. According to the American Cancer 
Society (ACS), approximately 19,240 African-American women in the United States 
were expected to be diagnosed with breast cancer during 2005, and approximately 5,640 
of these women were expected to die from it; an estimated 11,000 Hispanic women were 
diagnosed with breast cancer during 2003, and roughly 1,600 of these women died from 
it.  A potential explanation is that follow-up after an abnormal mammogram is delayed 
or incomplete, and thus, the benefits of screening are not being realized (ACS, 2003; 
ACS, 2005b; Jacobellis & Cutter, 2002; Yabroff et al., 2004). 
Screening Mammography 
Numerous studies have shown that early detection saves lives and increases 
treatment options.  Mammography is the single most effective method of early detection 
because it can identify cancer several years before physical symptoms develop.  
Screening mammography typically includes two views of each breast.  Mammography is 
highly accurate, but like most medical tests, it is not perfect. Generally, mammography 
will detect about 80%-90% of breast cancers in women without symptoms.  Recent 
estimates indicate that over a 10-year period of annual mammogram screenings, women 
confront a 50% cumulative risk of obtaining at least one false-positive mammogram 
(ACS, 2005a; Heckman et al., 2004; Kerlikowske et al., 2003).   
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Mammogram results are classified according to the American College of 
Radiology Breast Imaging Reporting and Data System (BIRADS) classifications (Table 
1): (0) indeterminate reading, more information needed; (1) normal; (2) benign or stable 
abnormality, standard screening follow-up recommended; (3) benign or stable 
abnormality, six month screening follow-up recommended; (4) suspicious abnormality, 
consider biopsy; and (5) highly suggestive of malignancy (Juarbe et al., 2005; American 
College of Radiology, 2004).   
 
Table 1. 
Radiology Breast Imaging Reporting and Data System (BIRADS) 
 
 
BIRADS 
Category 
What It Means 
0 More information is needed to give a final mammogram 
report. 
1 Your mammogram is normal. 
2 Your mammogram shows only minor abnormalities that are 
not suspicious for cancer. No additional testing is needed. 
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Abnormal Mammogram Results 
Although the overwhelming majority of women who undergo screening each 
year do not have breast cancer, a number of women have their mammograms interpreted 
as abnormal or inconclusive until further tests are performed.  Part of breast cancer 
screening is the assessment of abnormal screening results.  The assessment may involve 
physical examination, imaging with magnified or other special mammography studies, 
ultrasonography, imaging-directed biopsy, or surgical biopsy.  Fletcher (2000) states in a 
national study of mammography centers, 11% of mammograms require follow-up; 
others find approximately 6% to 7% of screening mammograms have abnormal findings.  
Elmore et al. (1998) reports if a woman 50 years old or older has ten mammograms, then 
the chance that she will have as least one false positive is approximately 56% and may 
be as high as 75%.  Lerman and Rimer (1995) project if 38% of the 48 million American 
women aged 40 and over have mammograms, then more than three million will have an 
indeterminate or positive test result every year.  About 5-20% of mammograms are in 
abnormal categories; of these, 6-18% will require some type of further examination.  
Yabroff et al. (2004) find prior studies report between 32% and 98% of women with 
abnormal mammograms receive at least some follow-up.  In addition, Yabroff et al. 
(2003) report approximately 9% of their sample, almost 1million women, do not 
complete any diagnostic follow-up after abnormal mammograms (ACS, 2005a; Olivotto 
et al., 2001). 
The most common and most worrisome mammographic abnormalities found on 
screening examinations that require further evaluation are masses and calcifications.  
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Each of these mammographic abnormalities can lead to several diagnoses including cyst, 
benign nonproliferative lesions, benign proliferative lesions with or without atypia, 
fibroadenoma radial scar intramammary lymph node, lipoma, galactoceles, ductal 
carcinoma in situ and invasive cancer for masses and benign nonproliferative lesions, 
benign proliferative lesions with or without atypia, fat necrosis, atherosclerosis, dermal 
lesion, ductal carcinoma in situ, and invasive cancer for calcifications (ACS, 2005a; 
Yabroff et al., 2004). 
Follow-up 
A screening mammogram does not diagnose cancer; rather, it identifies women 
with abnormalities who require follow-up.  Additional diagnostic procedures must be 
recommended, ordered, performed, and received to accomplish the goal of determining 
the presence or absence of disease.  Follow-up or additional testing (a) might rule out the 
presence of breast cancer; or (b) might confirm that cancer may indeed be present, 
thereby necessitating serious and invasive medical interventions.  Waiting for a 
definitive diagnosis after an abnormal screening mammogram can cause anxiety and 
distress for women, which may last for months.  Hislop et al. (2002) suggest that for 
women who are subsequently diagnosed with cancer, this initial period of distress may 
create difficulty with trust and confidence in the healthcare system, and may, for the 
remainder of women, deter further screening compliance.  Although identified as a 
significant concern, few studies have assessed the anxiety associated with the process 
from screening to definitive diagnosis (ACS, 2005a; Bastani et al., 2004; Heckman et al., 
2004; Olivotto et al., 2001). 
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Compliance 
The appropriate time span for follow-up after abnormal screening 
mammography, from notification of test results to diagnostic evaluation, has not been 
established.  Most studies that determine the timeliness of follow-up after abnormal 
screening mammography mark the beginning of the follow-up period as the index date 
of the abnormal screening examination.  The endpoint of the period is variously defined 
as the time it takes until the first diagnostic test; the time it takes to biopsy; the time 
spent completing the work-up; and the time spent on the final disposition. Appropriate 
follow-up of abnormal test results requires multiple steps and can take several weeks.   
Several studies in the literature document follow-up rates for abnormal breast 
cancer screenings.  These rates range from 50% to 93%, with the best follow-up being 
among women whose exam requires immediate follow-up (62%-93%).  Taplin et al. 
(2004) find that follow-up of abnormal mammograms is a quality-of-care issue that 
appears to account for a small proportion of the late-stage cancer issues among women.  
Although most abnormal studies turn out to be false positives, a significant proportion 
are associated with carcinoma, and all abnormalities require prompt follow-up care 
(Fillmore, Beekman, Johnson Farmer, & Gold, 2003; Karliner, Kaplan, Juarbe, Pasick, 
& Perez-Stable, 2005; Kerlikowske, 1996; Kerner et al., 2003; Poon et al., 2004). 
Mammography Results Notification 
Due to concerns regarding timely and appropriate notification of women about 
the results of their mammograms, the Mammography Quality Standards Act (MQSA) 
reauthorization (HR 4382) passed by Congress and effective since April 28, 1999, 
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include mandatory reporting of mammogram results directly to all patients, not only self-
referred patients.  This requirement states that the results should be provided as a 
“summary of the written report sent directly to the patient in terms easily understood by 
a lay person” (Federal Department of Agriculture, 2004, p. 12). This summary does not 
need to contain the detailed information that is sent to referring physicians or to self-
referred patients, but it must include specific information notifying the woman of how 
she should proceed.  The regulation requires that notification be sent in a timely manner 
(less than 30 days).  The American College of Radiologists (ACR) recommends that all 
centers have written procedures for transmission of the written summary report to the 
patient and requires a log or radiology information system (RIS) be used to track 
reporting.  In addition, MQSA and ACR specify that results with lesions that are 
suspicious or highly suggestive of malignancy should prompt the facility to make 
reasonable attempts to communicate with the patient as soon as possible.  
Mammography centers are required to be MQSA-certified in order to operate (ACS, 
2005a; Boudreau et al., 2004). 
Barriers to Follow-up 
The patient, the provider, and the system all contribute, in part, to inadequate 
follow-up. Patients, for example, may decide that they want a second opinion, may be 
worried about the cost, may be fatalistic, or may fear a painful procedure. Additionally, 
the patient may delay follow-up because she thinks the mammogram is normal and no 
further follow-up is necessary, because she does not have access to reliable 
transportation, because she does not have a usual source of care, because she worries 
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about cancer and is afraid of losing her breast, because she has difficulty arranging 
childcare, or worries about lost wages during the time that she has to take off work to 
receive follow-up.  Providers may delay follow-up when their work-up causes a delay, 
when they do not recommend appropriate follow-up, and when they misdiagnose the 
results.  System barriers to follow-up include delayed notification of results, scheduling 
delays, cancellations, difficulty in obtaining an appointment, long waits in the doctor’s 
office, and inconvenient facility hours (Bedell et al., 1995; Jones et al., 2005; Juarbe et 
al., 2005; Kaplan et al., 2004; Karliner et al., 2005; Kerner et al., 2003; McCarthy, 
Ulcickas Yood, Boohaker, et al., 1996; McCarthy, Ulcickas Yood, Janz, et al., 1996; 
Poon et al., 2004; Rojas & Mandelblatt, 1996; Strzelczyk & Dignan, 2002; Taplin et al., 
2004; Yabroff et al., 2004). 
Conceptual Framework 
Theory-based research over the past 20 years demonstrates how people use 
healthcare and how patients make decisions about whether or not to follow medical 
advice are influenced by individuals’ beliefs and perceptions in combination with 
environmental resources or barriers.  A summary of the literature on follow-up and 
Protection Motivation Theory suggests the health action a woman takes after being told 
her mammogram indicates a need for further testing or treatment has been strongly 
influenced by the following: 1) her understanding of the meaning of the abnormal 
results; 2) whether she believes she is at risk for breast cancer; 3) whether she believes 
that the medical recommendations will make a difference in her health; 4) whether she 
can follow the recommendation; and 5) what problems, barriers, and costs she will face 
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if she follows the recommendation (Ell et al., 2002; Floyd, Prentice-Dunn, & Rogers, 
2000; Maddux & Rogers, 1983; Milne, Sheeran, & Orbell, 2000; Rippetoe & Rogers, 
1987; Shelton & Rogers, 1981; Sturges & Rogers, 1996). 
Study Aims 
This research explores women’s experiences with follow-up after an abnormal 
mammogram and factors that influence follow-up through the use of a telephone 
interview.    Health status and possible barriers to follow-up variables, found in the 
barriers to cancer screening and treatment literature, are necessary in identifying 
variables which have the potential to affect a person’s perception, and promote or deter 
follow-up.  Protection Motivation Theory constructs utilized in this study are found in 
the literature to improve diagnostic health behaviors such as performing breast self-
examination and compliance with diagnostic test to identify a fictitious disease. 
The measures of outcome in this study are follow-up and no follow-up after an 
abnormal mammogram, and the predictors of each of these dependent variables. In this 
study, the definition of an abnormal mammogram is similar to that used by Kerlikowske 
(1996): quite simply, an abnormal mammogram necessitates further diagnostic testing.   
Independent variables, or variables that are associated with the outcome, include 
mammogram utilization, health insurance coverage, regular source of health care, cost, 
fear of getting breast cancer, expectations of the follow-up procedure, difficulty getting 
appointments, difficulty getting time off from work for medical appointments, difficulty 
finding transportation, and waiting a long time for medical appointments. 
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Theoretical Definition of Terms 
In this study, the definition of abnormal mammogram is similar to that used by 
Kerlikowske (1996): one that necessitates further diagnostic testing.   
Follow-up is defined as “diagnostic procedures recommended, ordered, 
performed or received to accomplish the goal of determining the presence or absence of 
disease” (Bastani et al., 2004, p. 1191). 
Significance of Research to Practice 
When interpretation of a screening mammogram indicates that additional 
diagnostic studies are needed, there should be no barriers or delay that would prevent the 
performance of further diagnostic tests.  Understanding the association between follow-
up and factors that influence follow-up may help identify strategies to improve follow-
up.  The progress to reduce breast cancer mortality remains a challenge and depends on 
the ability to institute the most effective approaches in prevention, early detection, 
follow-up, and treatment.  The challenge is to provide the best-quality care for women 
undergoing mammography screening by maximizing the benefits associated with a 
timely diagnosis of cancer (Committee on Gynecologic Practice, 2002; Barton et al., 
2004; Juarbe et al., 2005, Kaplan et al., 2004; Yabroff et al., 2004). 
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CHAPTER II 
REVIEW OF RESEARCH 
Conceptual Framework 
Coping and threat appraisal constructs of Protection Motivation Theory, along 
with moderators (demographic and health information) and questions found in the 
literature regarding barriers to follow-up (system, provider and patient delays), were 
chosen for this study to identify factors that influence follow-up and to serve as a guide 
in explaining the relationship of predictor variables to the outcome variable follow-up 
(see Figure 1).  Formulated research questions are based on a review of the literature on 
barriers to follow-up and the Protection Motivation Theory. 
The conceptual framework for this study was based on Protection Motivation 
Theory.  Prentice-Dunn et al. (2001) demonstrated that threatening health information 
prompts one to act in a variety of ways to minimize the perceived danger.  Prentice-
Dunn et al. (2001) corroborate the findings of others that emphasize personal 
vulnerability to breast cancer can be an effective means of motivating women to act to 
protect their health.  The addition of coping information moves the individual away from 
a maladaptive reaction to the threat.  Additionally, Floyd et al. (2000) and Milne et al. 
(2000) found that PMT constructs were useful in predicting the intention to change 
behavior.  Coping appraisal constructs had a stronger association with intention to 
change behavior then threat appraisal constructs.  In addition Milne et al. (2000) found 
that intentions are satisfactory predictors of health behaviors as PMT suggests.  
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Figure 1.  
Conceptual Framework for the Proposed Study: Measurements 
 
Moderators 
 
Demographics 
-race, age, SES 
 
Access to health 
care 
 
Health status 
 
Prior use of 
mammogram 
Coping Appraisal 
-Response efficacy 
-Self efficacy 
 
Noncompliance 
to follow-up of 
abnormal 
mammogram 
Threat Appraisal 
-Perceived vulnerability 
-Perceived severity 
-Fatalism 
Factors that Influence 
Follow-up 
-System delay 
-Provider delay 
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Overview of Protection Motivation Theory 
The original version of Protection Motivation Theory (PMT) grew out of 
research on fear appeals.  “A fear appeal is an informative communication about a threat 
to an individual’s well-being” (Milne, Sheeran, & Orbell, 2000, p. 107).  Additionally, 
PMT was introduced to operationally define the components of a fear appeal in order to 
determine the common variables that produce attitude change (Milne et al., 2000).  It 
was assumed that each component of a fear appeal would initiate a corresponding 
cognitive mediating process.  These processes, in turn, would influence protection 
motivation in the form of intention to adopt the recommended behavior contained within 
the fear appeal (Boer & Seydel, 1996; Floyd, Prentice-Dunn & Rogers, 2000; Helmes, 
2002; Maddux & Rogers, 1983; Milne, Orbell & Sheeran, 2002; Milne et al., 2000; 
Milne & Orbell, 2000; Prentice-Dunn, Floyd & Flournoy, 2001; Rippetoe & Rogers, 
1987; Rogers, 1975; Shelton & Rogers, 1981; Sturges & Rogers, 1996; Tanner, Day & 
Crask, 1989). 
PMT describes the processes involved in determining whether an individual will 
respond to a threat, such as a threat to health, by adopting a recommended coping 
response (Rogers 1975; Maddux & Rogers, 1983).  For example, PMT can help to 
determine whether an individual will be motivated to comply with the recommendation 
for a follow-up appointment after an abnormal mammogram.  PMT’s primary focus is 
aimed at two cognitive processes—threat appraisal and coping appraisal—that result in 
protection motivation (the motivation to perform or not perform a health behavior), 
which, in this study is operationally defined as the interest in and intention to comply 
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with follow-up recommendations after receiving abnormal results from a screening 
mammogram (Boer & Seydel, 1996; Floyd et al., 2000; Helmes, 2002; Maddux & 
Rogers, 1983; Milne et al., 2002; Milne et al., 2000; Milne & Orbell, 2000, Prentice-
Dunn et al., 2001; Rippetoe & Rogers, 1987; Rogers, 1975; Shelton & Rogers, 1981; 
Sturges & Rogers, 1996; Tanner et al., 1989). 
Threat appraisal is derived from the perceptions that one is personally vulnerable 
to a disease, combined with the beliefs that the disease in question would have severe 
consequences.  Perceived vulnerability assesses how personally susceptible an individual 
feels to the communicated threat.  Perceived severity assesses how serious the individual 
believes that the threat would be to his or her own life.  Where perceived vulnerability 
and perceived severity are high, an individual is presumed to experience a significant 
degree of personal threat.  The way in which a person responds to appraise threat is 
determined by coping appraisal (Boer & Seydel, 1996; Floyd et al., 2000; Helmes, 2002; 
Maddux & Rogers, 1983; Milne et al., 2002; Milne et al., 2000; Milne & Orbell, 2000; 
Prentice-Dunn et al., 2001; Rippetoe & Rogers, 1987; Rogers, 1975; Shelton & Rogers, 
1981; Sturges & Rogers, 1996; Tanner et al., 1989).   
In the original development of the theory, Rogers (1975) identified response 
efficacy as the main determinant of coping appraisal.  Response efficacy concerns 
beliefs that adopting a particular behavioral response will be effective in reducing 
disease threat. Maddux and Rogers (1983) expanded the components of coping appraisal 
to include self-efficacy and response costs in the coping appraisal component of the 
model.  Self-efficacy concerns an individual’s belief about whether or not he or she is 
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able to perform the recommended coping response.  Response costs consists of beliefs 
about how costly performing the recommended response would be to an individual 
(Boer & Seydel, 1996; Floyd et al., 2000; Helmes, 2002; Maddux & Rogers, 1983; 
Milne et al., 2002; Milne et al., 2000; Milne & Orbell, 2000; Prentice-Dunn et al., 2001; 
Rippetoe & Rogers, 1987; Rogers, 1975; Shelton & Rogers, 1981; Sturges & Rogers, 
1996).   
In summary, PMT proposes that an individual will adopt a protective behavior if 
he or she believes that the disease is severe and likely to occur and perceives the 
protective behavior to be effective in reducing the threat of the disease, carries a low 
cost, and is something they feel capable of doing.  PMT can explain and predict the 
motivation to change health behavior (Boer & Seydel, 1996; Floyd et al., 2000; Helmes, 
2002; Maddux & Rogers, 1983; Milne et al., 2002; Milne et al., 2000; Milne & Orbell, 
2000; Prentice-Dunn et al., 2001; Rippetoe & Rogers, 1987; Rogers, 1975; Shelton & 
Rogers, 1981; Sturges & Rogers, 1996). 
Summary of Research 
An extensive review of the literature and research on PMT indicates that it has 
been applied to a diverse array of topics, including areas of interest beyond health-
related issues.  PMT has been applied to injury prevention, environmental concerns, and 
protecting others.  It also has been widely applied to health-related behaviors.  In most of 
these studies, PMT has frequently been used as a framework for health education 
interventions designed to influence health behavior.  According to PMT, for example, 
pamphlet content can mediate adaptive protective health behavior.  The main fields of 
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application to date are reducing alcohol use, enhancing healthy lifestyles (e.g., 
promoting or increasing exercise, increasing the amount of calcium intake in the diet to 
prevent osteoporosis, and enhancing dental brushing and flossing), enhancing diagnostic 
health behaviors (e.g., the intention to perform breast self-examination and  the use of 
diagnostic test to identify a fictitious disease), and preventing disease (e.g., enhancing 
the intention to use condoms to prevent getting infected with HIV and sexually 
transmitted diseases).  The four central factors of PMT are well researched, and most 
studies found significant effects of the constructs of PMT on intention to adopt 
behavior(Boer & Seydel, 1996; Floyd et al., 2000; Helmes, 2002; Maddux & Rogers, 
1983; Milne et al., 2002; Milne et al., 2000; Milne & Orbell, 2000, Prentice-Dunn et al., 
2001; Rippetoe & Rogers, 1987; Rogers, 1975; Shelton & Rogers, 1981; Sturges & 
Rogers, 1996; Tanner et al., 1989). 
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CHAPTER III 
LITERATURE REVIEW 
Barriers to Follow-up 
Although barriers have been identified systematically as obstacles to obtaining 
screening mammograms and cancer treatment, few studies have examined barriers to 
follow-up of abnormal mammograms in the same manner, despite high rates of 
noncompliance.  Most studies have either looked at the barriers to cancer screenings and 
cancer treatment or have measured the follow-up rates for women with abnormal cancer 
screening results.  Some studies assume that inadequate follow-up or noncompliance 
with follow-up for abnormal mammograms have occurred infrequently or that the 
barriers to follow-up of abnormal mammograms have been identical to the barriers to 
cancer screenings and treatment (Barton et al., 2004; Bastani, Yabroff, Myers, & Glenn, 
2004; Bedell, Wood, Lezotte, Sedlacek, & Orleans, 1995; Boohaker, Ward, Uman, & 
McCarthy, 1996; Burack, Simon, Stano, George, & Coombs 2000; Fillmore, Beekman, 
Johnson Farmer, & Gold, 2003; Heckman et al., 2004; Hislop et al., 2002; Jones et al., 
2005; Juarbe et al., 2005; Kaplan, Crane, Stewart, & Juarez-Reyes, 2004; Karliner, 
Kaplan, Juarbe, Pasick, & Perez-Stable,  2005; Kerlikowske, 1996; Kerlikowske, Smith-
Bindman, Ljung, & Grady,  2003; Kerner et al., 2003; McCarthy, Ulcickas Yood, 
Boohaker, et al., 1996; McCarthy, Ulcickas Yood, Janz, et al., 1996; Myers, Balshem, 
Wolf, Ross, & Millner, 1993; Myers et al., 1999; Poon et al., 2004; Rojas & 
Mandelblatt, 1996; Strzelczyk & Dignan, 2002; Thorne, Harris, Hislop, & Vestrup 
(1999); Yabroff et al., 2004; Yabroff, Washington, Leader, Neilson, & Mandelblatt, 
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2003). 
The time involved in completing follow-up tests will be affected by a variety of 
conditions.  Causes of untimely follow-up after abnormal mammography are largely 
unknown.  There are three main types of delay that may contribute to untimely follow-up 
after an abnormal mammography: patient delay, provider delay, and system delay 
(Bastani et al., 2004; Bedell et al., 1995; Boohaker et al., 1996; Burack et al., 2000; 
Fillmore et al., 2003; Jones et al., 2005; Juarbe et al., 2005; Kaplan et al., 2004; Karliner 
et al., 2005; Kerlikowske, 1996; Kerlikowske et al., 2003; Kerner et al., 2003; 
McCarthy, Ulcickas Yood, Boohaker, et al., 1996; McCarthy, Ulcickas Yood, Janz, et 
al., 1996; Myers et al., 1993; Myers et al., 1999; Poon et al., 2004; Rojas & Mandelblatt, 
1996; Strzelczyk & Dignan, 2002; Thorne et al., 1999; Yabroff et al., 2004; Yabroff et 
al., 2003). 
Patient Delay 
Patient delay occurs when patients’ behaviors slow the follow-up process and 
include a prolonged decision-making period or refusal of further medical evaluation.  
Patient-induced delays may result from a fear of painful, invasive procedures (such as a 
biopsy), fear of losing a breast, fatalism, costs, inconvenient appointment hours, lack of 
knowledge of sources of care, history of infrequent or non-existent mammogram 
utilization, and worries about cancer.  Other factors cited less often include long waits in 
the clinic, transportation or child-care problems, and loss of pay.  Women also fail to 
complete follow-up after an abnormal mammogram because they feel too old for 
treatment, they feel that nothing is bothering them, they believe their physician has told 
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them that it is unnecessary, they have a low perceived risk of breast cancer, or they do 
not want to know if something is wrong (Bastani et al., 2004; Bedell et al., 1995; 
Boohaker et al., 1996; Burack et al., 2000; Fillmore et al., 2003; Guidry, Matthews-
Juarez, & Copeland,  2002; Kaplan et al., 2004; Karliner et al., 2005; Kerlikowske, 
1996; Kerner et al., 2003; McCarthy, Ulcickas Yood, Boohaker, et al., 1996; McCarthy, 
Ulcickas Yood, Janz, et al., 1996; Rojas & Mandelblatt, 1996; Yabroff et al., 2004; 
Yabroff et al., 2003). 
McCarthy, Ulcickas Yood, Boohaker, et al. (1996) and McCarthy, Ulcickas 
Yood, Janz, et al. (1996) found that factors associated with inadequate follow-up 
included no history of a mammogram prior to the initial screening mammogram and low 
socioeconomic status (SES).  These results are consistent with those of previous studies, 
which found low income to be associated with not keeping scheduled appointments even 
when cost was removed as a barrier.  However, Kerner et al. (2003) found no association 
between SES variables and timely resolutions of an abnormal breast finding.  In 
addition, McCarthy, Ulcickas Yood, Boohaker et al (1996) found that although most 
women apparently were notified of their results, many women with inadequate follow-
up may not understand that they need further evaluation and the importance of this 
evaluation.  Karliner et al. (2005) found that while 70% of their sample reported full 
understanding of their physician’s explanation of their mammogram, 30 % reported less 
than full understanding, and there were some differences by ethnicity and language. 
Women interviewed in a language other than English were less likely to report full 
understanding of their physicians’ explanation of their mammogram, with Asian women 
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being least likely to report full understanding.  Among the women with the most 
suspicious results, nearly half of these women did not understand that their mammogram 
was abnormal.  Kaplan et al. (2004) reported that women who are not clear about where 
to go to receive follow-up care may feel discouraged and may not invest the additional 
time needed to find out where to receive the appropriate care.  This problem may be 
compounded in larger facilities, where communication may falter because of a larger 
patient population.  Additionally, follow-up instructions can be confusing if care must 
take place at different sites within the hospital that are unfamiliar to the patients.  This is 
especially a concern for low-income and ethnic minorities, who may be at greater risk of 
getting lost in the system. 
A number of studies have found that women who receive abnormal screening 
results, including false-positive mammograms, experience a variety of emotions, 
including distress and anxiety.  In theory, the resolution of abnormal results should 
relieve these emotional states.  Many studies have documented an increase in anxiety 
among women with false-positive mammograms, with this anxiety lasting from less than 
one month to as long as three years after the screening mammogram.  Barton et al. 
(2004) found that three weeks after their mammograms, nearly 50% of the women who 
had false-positive mammograms reported having symptoms of anxiety about their 
mammograms, compared with 28% of women with normal mammograms.  Even three 
months after the mammogram, 28% of women with false-positive mammograms 
reported anxiety related to their mammogram.  Hass, Cook, Puopolo, Burstin, and 
Brennan (2000) found that substantial anxiety remains over an eight-month period for 
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many women who receive an abnormal mammogram result.  Heckman et al. (2004) 
found that women who were recalled for additional testing after receiving a suspicious 
mammogram reported significantly more breast pain, reduced sexual sensitivity, and 
elevated levels of anxiety, and women who received an abnormal screening 
mammogram but were later identified as being cancer-free engaged in significantly more 
breast and non-breast related medical visits than did women whose initial breast 
screening results were normal.  The consistency of this finding across many settings 
indicates the need for strategies to reduce the anxiety associated with abnormal 
mammogram results (Bastani et al., 2004; Burack et al., 2000; Hislop et al., 2002; 
Kaplan et al., 2004; Karliner et al., 2005; Kerner et al., 2003; Thorne et al., 1999; 
Yabroff et al., 2004; Yabroff et al., 2003). 
Although follow-up after an abnormal mammogram has not been extensively 
examined, most of these studies have looked at patient delays.  Few studies, however, 
have examined delays associated with health care provider and system-level health care 
delivery. 
Provider Delay 
Provider delays or delays that were attributed to the physician or other health 
care providers include misdiagnosis when cancer symptoms are ignored or when a 
suspect finding is not followed-up.  Boohaker et al. (1996) asserted that physician 
forgetfulness, belief that the abnormal findings were trivial, and the anticipation that the 
patient was expected in the clinic anyway have also been cited as being related to the 
lack of appropriate follow-up by physicians.  Additionally, Myers et al. (1999) found 
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that provider-related factors, such as years of experience, the belief that complete 
diagnostic evaluation is efficacious, and the perception that complete diagnostic 
evaluation is part of standard practice were associated with intention to complete 
diagnostic evaluation for abnormal colorectal findings (Bastani et al., 2004; Bedell et al., 
1995; Jones et al., 2005).  
System Delay 
Bedell et al. (1995) found that system delays or delays resulting from routine 
system practices at a facility, included general scheduling delays or time spent waiting 
for a physician and follow-up (diagnostic and/or surgery) appointments, postponement 
or cancellation of procedures, tests or appointments, delay in the reporting of test results 
or examination results to the provider, and unavailable or lost records that extended the 
follow-up time for the patient.  McCarthy, Ulcickas Yood, Janz et al. (1996) reported 
that females who reported getting medical appointments was very or moderately difficult 
were four times more likely to have inadequate follow-up (Bastani et al., 2004; Jones et 
al., 2005; McCarthy, Ulcickas Yood, Boohaker, et al., 1996).   
It is interesting that the few studies that look at system- and provider-related 
delays in conjunction with patient delays have cited provider and system delays to be the 
most common delays.  Bedell et al. (1995) found that nearly half of the delay in follow-
up resulted from system factors, such as general scheduling delays or times spent 
waiting for appointments and follow-up procedures to be scheduled and completed, 
waiting for reports of results, and waiting for retrieval of lost or missing records.  
Misdiagnosis was the most common reason for provider delay in follow-up.   
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Several studies have suggested that nonwhite women may experience delayed 
resolution of an abnormal mammogram result.  Chang et al. (1996) and McCarthy, 
Ulcickas Yood, Boohaker, et al. (1996) both reported possible differences in receipt of 
follow-up between racial/ethnic groups.  In a study conducted by Jones et al. (2005), 
over 28% of women who received abnormal or inconclusive results following a 
screening mammogram did not receive the recommended follow-up.  Several factors 
influenced whether or not a woman received adequate follow-up of an abnormal 
mammogram, including race/ethnicity.  Forty percent of African American women and 
18% of White women did not receive the recommended follow-up.  Kaplan et al. (2004) 
found that almost 9% of Latinas attending public health facilities did not receive any 
type of follow-up care.  Haas et al. (2000) did not demonstrate a difference in timeliness 
of care by race.  However, African American women in the Haas study were less 
satisfied with their care.  These results suggest that this dissatisfaction may create 
barriers for future care.  Ethnic disparities in survival that may be attributed to late-stage 
diagnosis suggest that management recommendations and social and cultural factors 
during screening follow-up procedures may affect outcomes (Juarbe et al., 2005; 
Karliner et al., 2005; Kerlikowske, 1996; Kerlikowske et al., 2003; Kerner et al., 2003; 
Rojas & Mandelblatt, 1996; Strzelczyk & Dignan, 2002; Yabroff et al., 2004; Yabroff et 
al., 2003). 
Cancer Fatalism 
A dearth of research exists in the area of cancer fatalism.  The difficulty 
experienced while investigating this area is that similarly related concepts such as 
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pessimism, powerlessness and helplessness have been used interchangeably with 
fatalism.  Although these perceptions are inherent in fatalism, cancer fatalism is “the 
belief that death is inevitable when cancer is present”, (Powe, Daniels, & Finnie 2005, p. 
318) and has been identified as a barrier to cancer screening, detection, and treatment, 
and can be viewed as a situational manifestation of fatalism in which the individual 
becomes entrapped in a cycle of late cancer diagnosis, limited treatment options and 
ultimately death.  Powe & Finnie (2003) state that cancer fatalism is most prevalent 
among African Americans, females, older people and people with low incomes and low 
educational levels (Powe, 1996; Powe & Weinrich, 1999; Powe & Finnie, 2003; Powe, 
Daniels, & Finnie, 2005). 
Factors that Influence Compliance 
Patients who have reported being told that they need follow-up for their 
abnormal mammogram results and who understand the follow-up plan were more likely 
to complete appropriate follow-up in a timely manner.  Patients who have reported 
asking questions during the initial screening examination and patients who reported 
being told by staff what would happen next if they had an abnormal result were more 
likely to complete follow-up in a timely manner.  Type of follow-up procedure 
recommended was significantly associated with receipt and adequacy of care.  For 
example, women who were referred for a follow-up clinical breast exam had lower odds 
of returning for care, and women referred for a six-month follow-up mammogram had 
lower odds of returning for follow-up care.  These women may have perceived such 
recommendations as indicative of a less serious abnormality and may have 
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underestimated the importance of returning for and completing their follow-up.  Hass et 
al. (2000) found that women received a more timely evaluation for their breast problems 
if they were older, belonged to a managed care plan, or had a more significant 
radiographic abnormality.  Kaplan et al. (2004) found that a small patient population, a 
patient's comfort with staff, a patient’s familiarity with the facility, and greater proximity 
of the different departments involved in follow-up care may all contribute to improved 
patient follow-up (Bastani et al., 2004; Bedell et al., 1995; Boohaker et al., 1996; Burack 
et al., 2000; Fillmore et al., 2003; Hislop et al., 2002; Jones et al., 2005; Juarbe et al., 
2005; Karliner et al., 2005; Kerlikowske, 1996; Kerlikowske et al., 2003; Kerner et al., 
2003; McCarthy, Ulcickas Yood, Boohaker, et al., 1996; McCarthy, Ulcickas Yood, 
Janz, et al., 1996; Poon et al., 2004; Rojas & Mandelblatt, 1996; Yabroff et al., 2004; 
Yabroff et al., 2003).  
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CHAPTER IV 
METHODOLOGY 
The purpose of this chapter is to describe how the research was conducted, 
including the study design and methods, setting and sample selection, protection of 
human subjects, procedures, operational definitions of concepts, measurements, and data 
analysis methods. 
Design 
A non-experimental, descriptive, cross-sectional design was used to identify the 
barriers to follow-up after an abnormal mammogram by 1) estimating the 
noncompliance rate of follow-up mammograms among women screened at an urban 
hospital’s mammography mobile unit in North Texas (October 1, 2004, to September 31, 
2005) who were found to need further evaluation for suspected abnormal findings; and 
2) identifying factors associated with noncompliance and perceived barriers to 
noncompliance (see Figure 1). 
Setting 
The urban hospital and six satellite clinics offer preventive medical services that 
include adult medicine, pediatrics, family planning, basic x-rays, lab work, dental 
services for children, and psychosocial services.  Moreover, the hospital provides 
screening mammograms to women aged 40 years and older at the six clinics.  
The mammography mobile unit has a regular schedule to visit five of the clinics.  
The frequency of the mobile unit visits to the clinics depends on the size of the clinic, 
the percentage of female patients aged 40 years and older, and the number of women 
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referred for a mammogram.  The sixth clinic has a stationary mammography unit, which 
is used for patients at that clinic and patients from the five other clinics who cannot 
climb the stairs of the mobile unit.  At each of the clinics, women are referred for a 
mammogram by their health care provider.  They are given an appointment and are 
called the day before the appointment as a reminder.  During fiscal year 2004/2005, the 
mammography mobile unit provided over 3,300 screening mammograms to clinic 
patients.  Care is provided regardless of the ability to pay.  Although other patients are 
treated in the hospital, clinics, and research programs, the poor and near poor are the 
target populations for the institution.  The outpatient population is an ethnically diverse 
group. 
At the screening mammogram, each patient completes a breast cancer 
assessment, which consists of demographics, family history of breast cancer, and history 
of breast cancer screenings (Appendix A).  Mammography Mobile Unit staff also teach 
mammogram patients individually or in a group how to perform breast self-exam by 
showing an American Cancer Society breast self-exam video.  They also discuss with 
patients when and how they will receive their results, what to do if their mammogram is 
abnormal, and what additional tests would need to be performed to determine whether it 
is breast cancer. 
Sample 
Because prior research was conducted on primarily Caucasian populations, this 
study was directed at indigent populations that are primarily minority.  The population  
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from which the sample was drawn consists of all women screened at a mammography 
mobile unit at five clinics during fiscal year 2004/2005 (October 1, 2004, to September 
31, 2005) who were found to need further evaluation for suspected abnormal findings.  
During fiscal year 2004/2005, the mammography mobile unit performed 3,336 
mammograms; 524 of the mammograms were found to be abnormal.  Of the 3,336 
women who received a mammogram 49% were African American, 35% were Hispanic, 
10% were White, 5% were Asian, and less than 1% were Native American (see Table 2).  
Of the 524 women who had mammograms found to be abnormal, 47% were African 
American, 32% were Hispanic, 15% were White, 2% were Asian, and 1% was Native 
American (see Table 3).  All female patients who had a screening mammogram during 
fiscal year 2004/2005 that produced abnormal results and who were referred for further 
diagnostic follow-up procedures or treatment were recruited for the proposed study. 
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Table 2. 
Screening Mammograms by Race 
2004/2005 Mammography Mobile Unit 
 
Race Number Percent 
African American 1635 49% 
Hispanic 1178 35% 
White 346 10% 
Asian 171 5% 
Unknown 5 <1% 
Native American 1 <1% 
Total 3336 100% 
 
 
 
Table 3. 
Abnormal Mammograms by Race 
2004/2005 Mammography Mobile Unit 
 
Race Number Percent 
African American 246 47% 
Hispanic 169 32% 
White 77 15% 
Asian 23 4% 
Native American 7 1% 
Unknown 2 <1% 
Total 524 100% 
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Sample Exclusions 
Women were excluded from the study if there was evidence of a previous 
diagnosis of breast cancer, previous surgical procedure, or previous follow-up procedure, 
such as a fine-needle aspiration, from an abnormal mammogram. Asian and Native 
American races were excluded from the study because of the small numbers of abnormal 
mammograms during the specified time (Asian—23 abnormal mammograms; Native 
Americans—seven abnormal mammograms).   
Protection of Human Subjects 
The study was approved by the Institutional Review Boards at Parkland Health 
and Hospital System, University of Texas Southwestern Medical School, and Texas 
A&M University (Appendix B).  The initial contact with the study subjects was through 
a study introduction letter from a health care provider.  The study subject was given a 
brief description of the study (general purpose, subject criteria, subject payment, and 
assurance of confidentiality) and was asked to return a signed Health Insurance 
Portability and Accountability Act (HIPAA) form in an enclosed stamped envelope.  
After a signed HIPAA was obtained, trained interviewers telephoned and attained verbal 
consent to interview subjects.  In the telephone script that interviewers read, subjects 
were told that their participation in the study was voluntary and were given again a brief 
description of the study.  Subjects were informed that they could withdraw from the 
study at any time, and were assigned a code before the interviewer began the telephone 
interview.  Subjects were informed that their name and other identifying information 
would not remain on the questionnaire and that results would remain with the researcher 
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in a secure location.  Subjects were also informed that only the investigator and research 
coordinator would have access to the subjects’ identification codes, which would be 
destroyed upon completion of the study. 
Procedure 
A medical provider practicing at the clinics initiated recruitment.  He sent 393 
letters to women screened at the mammogram mobile unit at the clinics during fiscal 
year 2004/2005 (October 1, 2004, to September 31, 2005).  The letter provided 
information about the study and asked the women to return a signed HIPAA 
authorization.  Trained interviewers called women who returned the signed HIPAA form 
and read the telephone script that asked if the women would consent to a telephone 
interview.  If the women consented to the telephone interview, the interviewer proceeded 
with the study questions (Appendix C).  Participants were informed that the general 
nature of the study was to investigate “things women can do to stay healthy”.  All 
participants were told that their participation was completely voluntary and that any 
information gathered would remain strictly confidential.  They were also made aware of 
their freedom to withdraw from the study at any time.  All participants were sent a 
$10.00 phone card upon completion of the questionnaire. 
The urban hospital required that members of their staff serve as interviewers and 
provided some recommendations.  Eight African American and Hispanic clinic staff 
members were selected.  Seven interviewers were bilingual.  They were paid a stipend.  
Interviewers attended two four-hour trainings prior to conducting the interviews.  During 
the first training, the principle investigator and research coordinator presented the nature 
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and purpose of the study, discussed the total survey process and the role of the 
interviewer, and reviewed the questionnaire.  The principal investigator read each 
question, identifying the type of question, how to record the answer, and how and when 
to probe for answers, stressing the importance of following the survey process (Aday, 
1996; Fowler, 1995).  Interviewers practiced reading the telephone script and 
administering the questionnaire to each other.  Interviewers were encouraged to read and 
study the telephone script and questionnaire and were asked to practice with a friend or 
family member during the week.  During the second training, interviewers posed 
problems and questions they had encountered while practicing.  Also, interviewers 
practiced while the principle investigator and research coordinator listened.  Although 
many of the interviewers had prior experience conducting telephone interviews, they 
were pleased that this study provided extensive training for them. 
Operational Definition of Concepts 
 The data on abnormal mammograms during fiscal year 2004/2005 was 
provided by the hospital.  The hospital provided demographic information of women 
who received an abnormal mammogram.  
 The data on follow-up of abnormal mammograms for fiscal year 2004/2005 was 
provided by the hospital.  The hospital provided the names of women who received 
follow-up and the names of women who did not receive follow-up. 
Measurement 
A 54-question questionnaire in both English and Spanish was used in this study 
(Appendix D). 
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Demographic Questions 
Five questions were asked to gather demographic data about age, level of 
education, marital status, work status, and income.  All questions except for one 
regarding income were adapted from the Behavioral Risk Factor Surveillance Survey 
2005 (CDC, 2005).  The Center for Disease Control, Behavioral Risk Factor 
Surveillance System (BRFSS) is the primary source of information on major health risk 
behaviors among Americans.  States use standard procedures to collect data through a 
series of monthly telephone interviews with U.S. adults.  Nationwide, the BRFSS 
collects data on risk behaviors in 24 categories, including demographics, health care 
access, health care utilization and women’s health.  After panel review the question 
about income was adapted from Bloom, Hayes, Saunders and Hodge, 1989 because that 
question was clearer (Table 4). 
Factors that Influence Follow-up Questions 
Several questions in the survey were developed by the investigator from factors 
identified in the literature as barriers to follow-up after an abnormal mammogram.  
Factors include, but are not limited to, the participant’s belief that the mammogram was 
normal and so no further follow-up was necessary, financial concerns/cost, inconvenient 
clinic hours, cancellation of follow-up appointments, long waits at the clinic, 
transportation difficulties, childcare issues, and loss of wages.  The purpose was to 
determine whether those factors would also be considered barriers in this population 
(Table 4).   
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Table 4. 
Instrument Variables by Question Numbers 
 
Variable Questions  
Demographics Question # 50, 51, 52, 53, 54 
Health Status Question # 1 
Regular source of care Question # 2, 3 
Insurance Question # 4 
Barriers to f/u 
     Costs 
     Transportation  
     Other Barriers 
 
Question # 5, 6, 12, 13 
Question # 7 
Question # 23a, b, c, d, e, f, g, h, I, j, k, l 
,m  
Prior mammogram Question # 8, 9, 10 
Mammogram recommended Question # 11 
Reason for mammogram Question # 14 
Mammogram results Question # 15, 16, 18, 18a 
Received f/u appointment Question # 17 
Understand results Question # 19 
Further evaluation f/u Question # 20, 21 
Diagnosed w/ cancer Question # 22 
Noncancerous surgery Question # 24, 25 
Family history Question # 26 
Clinical breast exam Question # 27, 28 
Breast Self Exam Question # 29, 30 
Protection Motivation Theory concepts 
     Severity 
     Vulnerability 
     Response Efficacy 
     Self-Efficacy 
     Rational Problem-Solving 
     Fatalism 
 
Question # 31, 34, 47 
Question # 32, 33, 35, 38,  
Question # 36, 41, 43, 45 
Question # 40, 44, 48, 49 
Question # 39,  
Question # 37, 42, 46 
 
Protection Motivation Questions 
A 20-question section adapted from Rippetoe’s (1985) research was used to test 
the participant’s perceived vulnerability to breast cancer, perceived severity of breast 
cancer, perceived response efficacy of mammography and follow-up exams to make a 
difference in her health, and perceived self-efficacy to determine if she can do what is 
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necessary to complete the recommendation.  The items were measured on a Likert scale 
with responses ranging from strongly disagree (1) to strongly agree (5) (Table 4). 
The questionnaire was translated into Spanish and back-translated into English 
by the hospital translators.   
The instrument was examined by a panel of experts - a researcher, statistician, 
health educator, social worker and nurse, all university faculty members.  Two focus 
groups – one English and one Spanish – with seven women in each group examined the 
questionnaire for content validity and to evaluate the vocabulary of the questionnaire.  It 
was then revised based on feedback from the experts and focus group participants 
(Aday, 1996; Fowler, 1995).  Focus group participants were either members of a breast 
cancer survivor group or had been screened at the hospital’s mammogram mobile unit.  
Additionally, the instrument was pretested as a telephone survey with 20 women who 
had been screened at the mammogram mobile unit to identify the time needed to  
complete an eight-page questionnaire and to identify possible problems associated with 
questions asked by telephone. 
The results from the focus groups indicated a need for participants to provide 
answers to sociodemographic data (i.e., age) rather than having to choose an answer 
from one of the prepared options.  Questions were also reworded for easier 
comprehension.  The results of the pretest indicated that the questions need to be asked 
slowly and clearly for participants to be able to understand and answer.  In addition, 
when reading statements that were measured on a Likert scale, interviewers needed to 
repeat possible Likert scale answers after each statement.  The time needed to complete 
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the questionnaire ranged from 15-20 minutes.  The women included in the pretest and 
focus groups were homogenous in age range, income, and educational level. 
Data Analysis 
The measures of outcome in this study are follow-up and no follow-up after an 
abnormal mammogram, and the predictors of each of these dependent variables.  The 
data on follow-up was provided by the hospital. 
Independent variables, or variables that are associated with the outcome, include 
demographic variables such as age and race, mammogram utilization, health insurance 
coverage, regular source of health care, and coping appraisal (response efficacy, self 
efficacy) and threat appraisal constructs (perceived vulnerability, perceived severity, fear 
arousal/fatalism).  Additional independent variables include factors found in the 
literature to influence follow-up such as difficulty getting appointments, difficulty 
getting time off from work for medical appointments, difficulty finding transportation, 
and waiting a long time for medical appointments. 
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CHAPTER IV 
 
RESULTS 
Data Analysis 
 Each completed questionnaire was coded with an identification number, and a 
log of the questionnaires was kept.  Data entry began as questionnaires were completed.  
All data was entered by the investigator using SPSS version 13.  All data were checked 
and cleaned by the investigator.  Exploratory analyses were conducted to determine the 
frequency of missing data.  With the exception of the variable income which had about 
14% missing data other variables had only 2% missing data. 
Description of Sample 
 As planned, subjects were recruited from the population of women screened at an 
urban hospital’s mammogram mobile unit at five satellite clinics during fiscal year 
2004/2005 (October 1, 2004, to September 31, 2005) who were found to need further 
evaluation for suspected abnormal findings.  On May 15, 2006, a medical provider 
practicing at the clinics, sent 393 letters to the subjects.  The letter provided information 
about the study and asked the women to return a signed Health Insurance Portability and 
Accountability Act (HIPAA) authorization, giving permission for contact, in an enclosed 
addressed and stamped envelope.  Twenty-one letters were returned due to wrong 
address and unable to forward.  One hundred and fifty-six women returned their signed 
HIPAA forms.  On June 13, 2006 a second letter with HIPAA form was sent to the 
remaining 216 women.  One hundred and fifteen women returned their signed HIPAA 
forms.  Data collection began on July 10, 2006, and was completed on August 11, 2006.  
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Four subjects declined to participate in the survey.  Reasons given included: (1) “did not 
want to take the time to complete the interview”; (2) “too tired to complete the 
interview”; (3) “under too much stress, and did not want to talk now”; and (4) “did not 
want the hospital to review her medical records”.  Two subjects began the interview and 
subsequently refused to complete the survey.  One subject said that she was tired of the 
questionnaire and wanted to stop, and the other said that the interviewer asked too many 
questions.  Three study subjects were not interviewed because interviewers could not 
contact them.  Full data analysis is reported for a final sample size of 262. 
Demographic Characteristics of Sample 
 Table 5 displays the frequency and percentage distribution of the demographic 
characteristics of the women in the sample.  The sample consisted of 262 participants, 
136 (52%) women who the hospital reported had not returned for follow-up and 126 
(48%) women who were reported to have returned.  The ages of the women in the 
sample ranged from 36 to 83 years, with a mean age of 55 and a median age of 54 
(SD=9.949).  Fifty percent of participants were African American, while 38% were 
Hispanic, and 12% were White.  Thirty percent of the participants preferred to be 
interviewed in Spanish.  Thirty percent of the participants were married, while 22% were 
divorced, 20% were widowed, 12% were separated, 13% reported being single, and 2% 
stated that they were a member of an unmarried couple and 1% refused to answer the 
question.  Forty-seven percent of participants stated that their household income was less 
than $10,000.00, and 82% of respondents stated that their income was less than 
$30,000.00.  Sixteen women stated that their husbands or family members handled all  
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Table 5. 
Demographic Characteristics of Sample 
 
Characteristic Frequency Percentage Cumulative 
Percentage 
Follow –up 
   Received follow-up 
   Did not receive follow-up 
 
126 
136 
 
48.1 
51.9 
 
48.1 
100.0 
Race 
   White 
   African American 
   Hispanic 
 
31 
132 
99 
 
11.8 
50.4 
37.8 
 
11.8 
62.2 
100.0 
Language 
   English 
   Spanish 
 
184 
78 
 
70.2 
29.8 
 
70.2 
100.0 
Marital Status 
   Married 
   Divorced 
   Widowed 
   Separated 
   Never been married (Single) 
   A member of an unmarried couple 
   Refused to answer 
 
79 
57 
52 
32 
33 
5 
4 
 
30.2 
21.8 
19.8 
12.2 
12.6 
1.9 
1.5 
 
30.2 
51.9 
71.8 
84.0 
96.6 
98.5 
100.0 
Income 
   Less than $5,000 
   $5,000 to $9,999 
   $10,000 to $19,999 
   $20,000 to $29,999 
   $30,000 to $39,999 
   $50,000 and over 
   Don’t know 
   Refused to answer 
 
57 
65 
65 
27 
10 
1 
16 
21 
 
21.8 
24.8 
24.8 
10.3 
3.8 
.4 
6.1 
8.0 
 
21.8 
46.6 
71.4 
81.7 
85.5 
85.9 
92 
100.0 
Employment 
   Employed for wages 
   Self-employed 
   Out of work for more than 1 year 
   Out of work for less than 1 year 
   Homemaker 
   Student 
   Retired 
   Refused to answer 
 
73 
14 
59 
11 
51 
2 
47 
5 
 
27.9 
5.3 
22.5 
4.2 
19.5 
.8 
17.9 
1.9 
 
27.9 
33.2 
55.7 
59.9 
79.4 
80.2 
98.1 
100.0 
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Table 5. 
Continued 
 
Characteristic Frequency Percentage Cumulative 
Percentage 
Education 
   Never attended school or kindergarten only 
   Grades 1 through 8 (Elementary) 
   Grades 9 through 11 (Some high school) 
   Grades 12 or GED (High school graduate) 
   College 1 year to 3 years (Some college or  
   Technical school) 
   College 4 years or more (College graduate) 
   Refused to answer 
 
7 
62 
54 
82 
36 
 
15 
6 
 
2.7 
23.7 
20.6 
31.3 
13.7 
 
5.7 
2.3 
 
2.7 
26.3 
46.9 
78.2 
92.0 
 
97.7 
100.0 
Age Mean age 55 
Median age 54 
Standard deviation  9.949 
Minimum age 36 
Maximum age 83 
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financial matters and that they were unaware of their total household income.  Thirty-
three percent of respondents were employed, while 27% were unemployed, 20% were 
homemakers, and 18% were retired.  Only 6% of respondents graduated from college, 
14% had some college, 31% graduated from high school or obtained a GED, and 21% 
had some high school education.  Twenty-six percent of respondents had less than an 
eighth-grade education. 
Collinearity 
Twenty statements adapted from Rippetoe’s (1985) research and used to test the 
participants’ protection motivation were determined to be part of either the coping 
appraisal or threat appraisal constructs (Table 6).   “Collinearity involves the relationship 
of the independent variables (predictors) to one another” (Kleinbaum, Kupper, Muller, & 
Nizam 1998, p.237).  The statements were then examined for collinearity (Table 7), and 
variables with high collinearity (Questions 36, 40, 44, and 45) were deleted (Table 8).  
The remaining variables were used in further analysis.  There were no variables with 
very high collinearity in the Threat Appraisal variables; therefore, no variables were 
deleted (Table 9). 
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Table 6. 
Protection Motivation Statements by Construct 
 
Coping Appraisal 
Response Efficacy 
36. Having regular mammograms is the best, most effective method of detecting breast 
cancer early. 
41. Having a yearly mammogram will not drastically improve my chances of surviving 
breast cancer. 
43. If I get regular mammograms, my chances of detecting breast cancer are extremely 
high. 
45. If I have an abnormal mammogram, I believe that the cancer will be detected early 
and I will survive. 
Self-efficacy 
40. If I have an abnormal mammogram, I can go to the follow-up exams.  
44. If I have an abnormal mammogram, I believe I can get all the follow-up exams. 
48. Other women are more capable of going to follow-up appointments than I am. 
49. Going to follow-up exams are easy to do. 
Threat Appraisal 
Perceived vulnerability 
32. There is a good probability that cancer may now be developing in my breast.  
33. I am more vulnerable to breast cancer than anyone else. 
35. My chances of developing breast cancer are small. 
38. I am currently at risk for developing breast cancer. 
Perceived severity 
31. In spite of advances in modern medicine, breast cancer is as serious and dangerous a 
disease as it was several years ago. 
34. The majority of women who develop breast cancer have serious emotional as well as 
physical side-effects. 
47. Even with advanced medical procedures, the best treatment for cancer involves 
radical surgical techniques. 
Fatalism  
37. There are so many ways to get cancer today, it’s just a matter of time; I might as well 
just try and accept it. 
42. Only time will tell if I develop breast cancer; nothing can be done anyway but wait. 
46. If you are destined to die of breast cancer, you will; there is really little you can do 
about it. 
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Table 7. 
Correlation of Coping Appraisal Variables 
 
Coping 
Appraisal 
Statements 
Q 36 
Mammogram 
most 
effective 
method (RE) 
Q 40 
I can go 
to f/u 
exams 
(SE) 
Q41 
Mammogram 
will not 
improve 
survival (RE) 
Q43 
Chances 
of 
detecting 
BrCa is 
high 
(RE) 
Q44 
I believe 
I can get 
f/u  
exams 
(SE)  
Q 45 
Cancer 
will be 
detected 
early 
(RE) 
Q48 
Others 
more 
capable 
of getting 
f/u 
(SE) 
Q49 
F/u 
is 
easy 
(SE) 
Q 36 
Mammogram 
most 
effective 
method (RE) 
 
1 
      
 
Q 40 
I can go to 
f/u exams 
(SE) 
 
.759(**) 
 
1 
     
 
Q41 
Mammogram 
will not 
improve 
survival (RE) 
 
 
.197(**) 
 
 
.401(**) 
 
 
1 
    
 
Q43 
Chances of 
detecting 
BrCa is high 
(RE) 
 
 
.574(**) 
 
 
.382(**) 
 
 
.075 
 
1 
   
 
Q44 
I believe I 
can get f/u  
exams 
(SE) 
 
 
.706(**) 
 
 
.901(**) 
 
 
.320(**) 
 
 
.411(**) 
 
1 
  
 
Q 45 
Cancer will 
be detected 
early 
(RE) 
 
 
.708(**) 
 
 
.585(**) 
 
 
.158(*) 
 
 
.646(**) 
 
 
.605(**) 
 
1 
 
 
Q48 
Others more 
capable of 
getting f/u 
(SE) 
 
 
-.358(**) 
 
 
-.177(**) 
 
 
.009 
 
 
-.233(**) 
 
 
-.270(**) 
 
 
-.354(**) 
 
1 
 
Q49 
F/u is easy 
(SE) 
 
.752(**) 
 
.956(**) 
 
.380(**) 
 
.422(**) 
 
.917(**) 
 
.622(**) 
 
-.171(**) 
 
1 
 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
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Table 8. 
Correlation of Coping Appraisal after Reduction 
  
Coping Appraisal 
Statements 
Q41 
Mammogram will not 
improve survival (RE) 
Q43 
Chances of detecting 
BrCa is high (RE) 
Q48 
Others more capable 
of getting f/u 
(SE) 
Q49 
F/u is 
easy 
(SE) 
Q 36 
Mammogram 
most effective method 
(RE) 
 
 
   
Q 40 
I can go to f/u exams (SE) 
 
 
   
Q41 
Mammogram will not 
improve survival (RE) 
 
1 
   
Q43 
Chances of detecting BrCa 
is high (RE) 
 
.382(**) 
 
1 
  
Q44 
I believe I can get f/u  
exams 
(SE) 
 
.320(**) 
 
.411(**) 
  
Q 45 
Cancer will be detected 
early 
(RE) 
 
 
.158(**) 
 
 
.646(**) 
 
  
Q48 
Others more capable of 
getting f/u 
(SE) 
 
 
.009 
 
 
-.233(**) 
 
 
 
1 
 
Q49 
F/u is easy 
(SE) 
 
.380(**) 
 
.422(**) 
 
-.171(**) 
 
1 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
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Table 9. 
Correlation of Threat Appraisal 
 
Threat 
Appraisal 
Statements 
Q 31 
BrCa serious 
disease (S) 
Q32 
Ca now  
developing 
in breast (V) 
Q 33 
Vulnerable 
to BrCa  (V) 
Q34 
Serious 
emotional  
side effects 
(S) 
Q35 
Chances of  
getting BrCa 
small (V) 
Q 31 
BrCa serious 
disease (S) 
 
1 
    
Q32 
Ca now  
developing 
in breast (V) 
 
 
.404(**) 
 
 
1 
   
Q 33 
Vulnerable 
to BrCa  (V) 
 
.451(**) 
 
.585(**) 
 
1 
  
Q34 
Serious 
emotional  
side effects 
(S) 
 
 
 
.615(**) 
 
 
 
.433(**) 
 
 
 
.465(**) 
 
 
1 
 
Q35 
Chances of  
getting BrCa 
small (V) 
 
 
-.425(**) 
 
 
-.474(**) 
 
 
-.611(**) 
 
 
-440(**) 
 
 
1 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
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Table 9. 
Continued 
 
Threat 
Appraisal 
Statements 
Q37 
Accept 
breast 
cancer (F) 
Q38 
At risk for 
developing 
BrCa (V) 
Q42 
Time will 
tell if Iget 
BrCa (F 
Q46 
Little you 
can do about 
BrCa 
(F) 
Q 47 
Best 
treatment – 
radical 
surgery 
(S) 
Q37 
Accept 
breast 
cancer (F) 
1 
 
    
Q38 
At risk for 
developing 
BrCa (V) 
 
.486(**) 
 
1 
   
Q42 
Time will 
tell if I get 
BrCa (F 
 
.855(**) 
 
.500(**) 
 
1 
 
  
Q46 
Little you 
can do about 
BrCa 
(F) 
 
 
.862(**) 
 
 
.534(**) 
 
 
.892(**) 
 
 
1 
 
Q 47 
Best 
treatment – 
radical 
surgery 
(S) 
 
 
.414(**) 
 
 
.472(**) 
 
 
.519(**) 
 
 
.514(**) 
 
 
1 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
 
 
Instrumentation 
 Internal consistency reliability “measures the extent to which performance of any 
one item on an instrument is a good indicator of performance on any other item in the 
same instrument” (Waltz, Strickland, & Lenz, 1991, p. 166).  Cronbach’s coefficient 
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alpha was computed to determine the internal consistency of the 20-question section 
adapted from Rippetoe’s (1985) research that was used to test a participant’s protection 
motivation.  The resulting alpha coefficients were:  Coping Appraisal = .76 and Threat 
Appraisal = .70 (Tables 10 and 11).  The resulting alpha coefficients for each construct 
were: Severity = .84, Vulnerability = .31, Response Efficacy =.57, Self-Efficacy = .68, 
and Fatalism =.95 (Table 12).  These results were somewhat consistent with Rippetoe’s 
(1985) results that determine the alpha coefficients: “Severity = .78, Vulnerability = .67, 
Response Efficacy = .86, Self-Efficacy = .78, and Fatalism = .66” (Rippetoe, 1985, p. 
50).  In addition, these results indicate that the measures were satisfactory. 
 
Table 10. 
Reliability Statistics for Coping Appraisal 
 
Cronbach's 
Alpha 
N of 
Items 
.762 11 
 
 
Table 11. 
Reliability Statistics for Threat Appraisal 
 
Cronbach's 
Alpha 
N of 
Items 
.703 8 
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Table 12. 
Reliability Statistics for Severity, Vulnerability, Response Efficacy, Self-Efficacy 
and Fatalism 
 
Construct Cronbach's 
Alpha 
N of 
Items 
Severity .844 3 
Vulnerability .305 4 
Response 
Efficacy .567 4 
Self-Efficacy .678 4 
Fatalism .952 3 
 
 
T-test and ANOVA Comparisons 
 Women who obtained follow-up were compared to those who did not obtain 
follow-up.  Analysis using t-tests were performed on the following variables: age, 
education, income, health status, time since last mammogram, and number of 
mammograms in last five years (Table 13).  Subjects were similar in their report of these 
variables.  Analyses using ANOVA were conducted on the following variables: marital 
status, obtaining clinical breast exam, and race (Table 14).  There were no significant 
differences between women who obtained follow-up and those who did not obtain 
follow-up.   
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Table 13. 
T-tests to Determine Differences between the Two Groups of Women (Follow-Up 
and No Follow-Up) 
 
Levene’s 
Test for 
Equality of 
Variances t-test for Equality of Means 
95% 
Confidence 
Interval of the 
Difference 
 F Sig. T df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference Lower Upper 
Follow-
Up 1.649 .200 -.318 260 .750 -.393 1.232 -2.819 2.034 
Age 
No 
Follow-
Up 
    -.317 253.314 .751 -.393 1.236 -2.828 2.043 
Follow-
Up .653 .420 .393 254 .695 .061 .155 -.245 .367 
Education 
No 
Follow-
Up 
    .393 253.054 .694 .061 .155 -.245 .367 
Follow-
Up .804 .371 
-
2.421 223 .016 -.373 .154 -.676 -.069 
Income 
No 
Follow-
Up 
    
-
2.441 222.610 .015 -.373 .153 -.673 -.072 
Follow-
Up .024 .877 -.272 260 .786 -.027 .100 -.223 .169 
Health 
status 
No 
Follow-
Up 
    -.272 259.217 .786 -.027 .100 -.223 .169 
Follow-
Up .006 .938 -.095 260 .925 -.089 .941 -1.941 1.763 
Time 
since last 
mamm No 
Follow-
Up 
    -.095 256.589 .925 -.089 .942 -1.944 1.766 
Follow-
Up .062 .803 
-
1.379 260 .169 -.266 .193 -.645 .114 
How 
many 
mamm in 
5 yrs 
No 
Follow-
up 
    
-
1.380 259.265 .169 -.266 .192 -.645 .113 
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Table 14. 
ANOVA Tests to Determine Differences between the Two Groups of Women 
(Follow-Up and No Follow-Up)  
 
 
  
Sum of 
Squares Df Mean Square F Sig. 
Between 
Groups .606 1 .606 1.411 .236 
Within Groups 111.745 260 .430     
Race 
Total 112.351 261       
Between 
Groups .000 1 .000 .000 .998 
Within Groups 541.674 256 2.116     
Marital 
Status 
Total 541.674 257       
Between 
Groups .038 1 .038 .302 .583 
Within Groups 32.527 260 .125     
CBE 
Total 32.565 261       
 
Logistic Regression Model  
A logistic regression model was performed using follow-up as the dependent 
variable.   Independent variables used in the model included demographic variables such 
as, race, age, education, marital status, employment, income, health status, mammogram 
utilization, health insurance coverage, and regular source of health care.  Other variables 
found in the literature that influence follow-up were included in the model,  such as 
difficulty getting appointments, difficulty getting time off of work for medical 
appointments, difficulty finding transportation, and waiting a long time for medical 
appointments.  Constructs for Protection Motivation Theory were utilized to determine if 
perceived vulnerability, perceived severity, fatalism, response efficacy, and self-efficacy 
were associated with the outcome variable follow-up.  
Table 15 summarizes the outcome of the model.  The variables most related to 
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follow-up were (1) number of mammogram in the last 5 years (OR=8.795); (2) having 
health insurance (OR=5.941); (3) having problems receiving abnormal mammogram 
results (OR=3.852); (4) having problems receiving or making a follow-up appointment 
(OR=7.739); (5) taking off from work for the follow-up appointment (OR=4.105); (6) not 
having transportation to follow-up appointment (OR=4.171); and (7) waiting a long time 
to receive the follow-up appointment (OR=6.454).   
Protection Motivation Theory constructs listed in Table 6 had no statistically 
significant association with the outcome variable follow-up. 
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Table 15. 
Logistic Regression 
 
Independent Variables B S.E Odds 
Ratio 
Sig. 
95.0% C.I. for EXP(B) 
     Lower Upper 
Race .339 .349 .943 .332 .708 2.782 
Age -.005 .022 .045 .831 .953 1.040 
Education -.138 .161 .731 .392 .635 1.195 
Marital Status .144 .130 1.211 .271 .894 1.491 
Employment -.188 .101 3.501 .061 .680 1.009 
Income .146 .182 .644 .422 .810 1.654 
Health Status .076 .225 .112 .737 .693 1.677 
# of mammograms in last 5 years .388 .131 8.795 .003 1.140 1.903 
When last mammogram .501 .258 3.784 .052 .996 2.735 
Insurance 3.221 1.321 5.941 .015 1.880 334.020 
Regular source of care 21.517 20658.580 .000 .999 .000 . 
Problem receiving results -1.619 .825 3.852 .050 .039 .998 
Problem making/receiving f/u appointment 1.455 .523 7.739 .005 1.537 11.934 
Hospital canceling f/u appt. -42.138 35102.842 .000 .999 .000 . 
Mammogram results lost -.075 .904 .007 .934 .158 5.453 
Hospital rescheduling f/u appt. 19.700 28405.932 .000 .999 .000 . 
F/U appt. inconvenient .155 1.025 .023 .880 .157 8.697 
Take off work for f/u appt. 1.586 .783 4.105 .043 1.053 22.662 
No transportation to f/u appt. -1.478 .724 4.171 .041 .055 .942 
Problem paying for exam -.486 .585 .692 .406 .195 1.934 
Receiving unexpected bill for f/u -.303 1.877 .026 .872 .019 29.242 
Insurance covering f/u 2.496 1.530 2.661 .103 .605 243.515 
Waiting to receive the f/u appt. -2.017 .794 6.454 .011 .028 .631 
Waiting to be seen by dr. at f/u 1.363 .758 3.239 .072 .886 17.260 
BrCa is a serious disease .115 .279 .171 .680 .649 1.940 
Cancer may be developing in Br  -.187 .361 .270 .604 .409 1.682 
More vulnerable to BrCa -.697 .519 1.800 .180 .180 1.379 
Women BrCa serious side-effects -.281 .368 .582 .446 .367 1.554 
My chances of getting BrCa are small .805 .444 3.283 .070 .936 5.339 
Mamm. best way to detect BrCa -.110 1.043 .011 .916 .116 6.919 
Just a matter of time to get BrCa .313 .578 .293 .588 .441 4.241 
I am at risk for developing BrCa .917 .584 2.460 .117 .795 7.864 
Prospect of BrCa makes me get mamm.  2.081 1.590 1.712 .191 .355 180.849 
I can go to the f/u exam -2.764 2.571 1.156 .282 .000 9.732 
Yearly mamm will not improve chances .236 .330 .513 .474 .663 2.419 
Time will tell if I develop BrCa .307 .539 .324 .569 .472 3.910 
Mamm detect BrCa high .057 .758 .006 .940 .240 4.683 
I can get all f/u exams -.498 1.389 .129 .720 .040 9.236 
Cancer will be detected early .408 1.179 .120 .729 .149 15.156 
Destined to die of BrCa -.421 .513 .675 .411 .240 1.793 
Best trmt. is radical surgical tech. .051 .383 .018 .894 .496 2.231 
Other women more capable of f/u -1.298 .724 3.211 .073 .066 1.129 
Going to f/u is easy to do .804 2.016 .159 .690 .043 116.181 
Constant 15.540 46130.535 .000 1.000     
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CHAPTER VI 
DISCUSSION, IMPLICATIONS, RECOMMENDATIONS, AND CONCLUSIONS 
In this final chapter, a discussion about the process of conducting the research will 
precede an overview of the study’s significant findings.  These findings will be discussed 
in relation to existing research studies, variable relationships, and applicability of the 
theoretical model.  Limitations of the study that may affect the validity or the 
generalizability of results will also be reviewed.  Implications for health education 
practice will be addressed, followed by recommendations for future research and 
conclusions. 
Conducting the Research 
 The implementation of this telephone survey was feasible and did not place undue 
burden on subjects.  Two hundred seventy-one women returned their Health Insurance 
Portability and Accountability Act (HIPAA) forms.  There was no excess burden on 
interviewers conducting the telephone interviews.  Staff indicated that the length of the 
interview was short enough for them to conduct interviews many times throughout the 
day.  Interviewers also stated that several subjects, at the end of the interview, expressed 
appreciation for the opportunity to participate in the study.  Subjects said that 
participation in the study increased their awareness and compelled them to reflect on their 
health and other issues in their lives.  Several study participants who did not obtain 
follow-up asked the interviewers for assistance in obtaining their results and 
appointments for follow-up exams.  In addition, several Spanish-speaking participants 
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asked interviewers to explain their results in Spanish and to assist them in obtaining 
follow-up appointments.   
Relationships of Variables to Outcome 
Number of Mammograms in the Last Five Years 
 There was a significant positive relationship between the independent variable 
“number of mammograms in the last five years” and the outcome variable follow-up.  
Women who had a higher number of mammograms in the last five years were more 
likely to obtain follow-up for their abnormal mammogram.  This relationship is supported 
by the literature.  McCarthy, Ulcickas Yood, Janz, et al. (1996) stated that females who 
reported during the interview that they had one or two mammograms in the past five 
years were four times more likely to receive inadequate follow-up compared to women 
who had had three to four mammograms (McCarthy, Ulcickas Yood, Boohaker, et al., 
1996; McCarthy, Ulcickas Yood, Janz, et al., 1996). 
Insurance 
 Whether or not the study respondent reported having insurance also had a 
significant positive relationship with the dependent variable follow-up.  Forty-eight 
percent of participants in this study reported having health care coverage, including 
private insurance or government plans such as Medicare and Medicaid, and an additional 
47% of study subjects stated that they were enrolled in the hospital’s health plan.  
Similarly, Juarbe et al. (2005) found that 95% of the women in their study were insured.  
One study reported that women received a more timely evaluation for abnormal 
mammogram results if they belonged to a managed health care plan, while another study 
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stated that women who had no health insurance had a lower compliance with follow-up.  
Because most of our study participants had insurance, this study may not accurately 
reflect the challenges of having no insurance in the evaluation of abnormal mammograms 
(Haas et al., 2000; Juarbe et al., 2005; Strzelczyk & Dignan, 2002).  
Did You Have Problems with Receiving Mammogram Results? 
 Several studies (Bedell et al., 1995, Chang et al., 1996, and McCarthy, Ulcickas 
Yood, Janz, et al., 1996) identified problems receiving mammogram results as a barrier to 
completing follow-up.  Chang et al. (1996) surmised that these problems might be the 
result of incorrect contact information and effectiveness of communication between 
provider and patient.  In this study, the variable of a problem receiving mammogram 
results had a surprisingly negative relationship with follow-up.  Women who reported 
receiving their mammogram results still did not go for follow-up.  This finding is 
important because it points out that there is another factor here influencing participants’ 
decisions not to complete follow-up.  Perhaps even though respondents received their 
results, they did not understand them or the importance of obtaining follow-up (Bedell et 
al., 1995; Chang et al., 1996; McCarthy, Ulcickas Yood, Janz, et al., 1996). 
Did you Have Problems with Receiving/Making Follow-up Appointment? 
 Respondents who reported having difficulty making or receiving their follow-up 
appointments were more likely not to obtain follow-up.  Several studies in the literature 
concurred with this finding.  Hislop et al. (2002) reported this as the most frequently 
reported delay among women in their study (Bedell et al., 1995; Chang et al., 1996; 
Hislop et al., 2002; McCarthy, Ulcickas Yood, Janz, et al., 1996). 
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Did You Have Problems with Having to Take Off Work? 
 Women in this study who reported having a problem taking time off from work 
for their follow-up appointment were more likely not to obtain their follow-up exams.  
Only one other study in the literature looked at this variable.  Rojas and Mandelblatt 
(1996) stated that non-compliers to follow-up frequently reported barriers that included 
loss of pay due to having to take time off from work (Rojas & Mandelblatt, 1996). 
Did You Have Problems with Not Having Transportation to the Follow-up Appointment? 
 Women in this study who reported having problems with transportation to their 
follow-up appointments were more likely not to obtain follow-up care.  The study 
conducted by Kaplan et al. (2004) agreed with our findings that women are less likely to 
return for follow-up if they have problems with transportation.  This positive relationship 
between the outcome variable of follow-up and the variable of transportation has been 
discussed in the literature several times (McCarthy, Ulcickas Yood, Boohaker, et al., 
1996; McCarthy, Ulcickas Yood, Janz, et al., 1996). 
Did you Have Problems with Waiting a Long Time to Receive the Follow-up 
Appointment? 
 Study participants who reported having to wait a long time before receiving a 
follow-up appointment were more likely not to get follow-up care.  Bedell et al. (1995) 
concurred with this finding.  In Bedell et al.’s (1995) study, nearly half of the diagnostic-
interval delay in the public hospital resulted from system factors, such as time spent 
waiting for appointments and diagnostic procedures to be scheduled.  In Bedell et al.’s 
(1995) study, this finding was one of the most striking differences observed between the 
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public and private sites of care.  This is especially of concern since the women acquiring 
health care services at public hospitals are more likely to be indigent and ethnic 
minorities and may be at a greater risk of getting lost in the system. 
Overview of Other Significant Findings 
 The most prominent finding in this study is the disturbingly high percentage 
(52%) of women who did not obtain follow-up care after notification of their abnormal 
mammogram.  Several studies in the literature also found high percentages of women not 
complying with recommended follow-up.  Yabroff et al. (2004) found that prior studies 
have reported that between 32% and 98% of women with abnormal mammograms 
receive at least some follow-up.  In addition, Yabroff et al. (2003) reported that 
approximately 9% of their sample, almost one million women, did not complete any 
diagnostic follow-up after abnormal mammograms.  Kerner et al. (2003) found that 39% 
of women in their study were found not to have completed diagnostic examinations, 
while Kaplan et al. (2004) found that over 90% of the women in their study returned for 
some follow-up care.  Given the impressive increase in proportion of women receiving 
screening mammograms, it is critical that we ensure that women who have made the 
effort to obtain screening mammograms receive the maximum benefit from the screening 
tests.  In addition, even though lack of follow-up for a specific abnormal mammogram 
may not be associated with a diagnosis of advanced breast cancer, women without cancer 
who do not complete any diagnostic follow-up may also fail to return for breast cancer 
screening and/or may delay seeking care should they have breast cancer symptoms in the 
future.  
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 Subjects in this study were likely to have a regular source of care (99%) at the 
clinics where they received their mammograms.  Studies in the literature suggest that 
women who have poorer access to care because they are likely to have no regular source 
of care are less likely to obtain follow-up care.  Cost was not considered a barrier in this 
study because 48% of respondents reported having health care coverage, including 
private insurance or government plans such as Medicare and Medicaid.  Additionally 
47% of study subjects stated that they were enrolled in the hospital’s health plan.  
Moreover, only 3% of women stated that within the last year, they had needed to see a 
doctor but could not do so because of the cost, and only 4% stated that within the last 
year, they had needed prescribed medication but could not buy it because of costs.  
Kaplan et al (2004) found that women were less likely to return for follow-up care if they 
reported inability to pay for the care.  Several other studies report similar findings 
(McCarthy, Ulcickas Yood, Boohaker, et al., 1996; McCarthy, Ulcickas Yood, Janz, et 
al., 1996; Rojas & Mandelblatt, 1996). 
 Overall, in regards to mammogram utilization, 78% of subjects in this study 
reported having a mammogram within the past year, and 30% reported having five 
mammograms in the last five years.  This is comparable with the Centers for Disease 
Control and Prevention’s national and Texas data on mammography utilization.  In 2004, 
74.9% of women nationally and 67.8 % of women in Texas stated that they had had a 
mammogram in the last two years (CDC, 2004).  Ninety percent of study participants 
reported having a clinical breast exam by a doctor or other health professional, and 45% 
of respondents stated that they had had a clinical breast exam within the last year.  
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Eighty-five percent of respondents said that they knew how to examine their breast for 
lumps, and 39% said that they performed breast self-exam once a month.   
 According to McCarthy, Ulcickas Yood, Boohaker, et al. (1996), although most 
women were notified of their results, many women with inadequate follow-up may not 
understand that they need further evaluation and the importance of this evaluation.  
Women in this study who did not obtain follow-up were more likely not to understand the 
results (33%) than women who did get follow-up (2%).  These results are similar to those 
in Karliner et al. (2005), who found that 30% of their sample reported not understanding 
their physician’s explanation of their mammogram.  Furthermore, 77% of women who 
did not obtain follow-up reported that they were not told they needed further evaluation, 
while 71% stated that they never received a follow-up appointment after receiving their 
mammogram results. 
Limitations 
 There were several limitations to this study.  First of all, patients were not 
randomly selected; only women who returned their HIPAA forms were interviewed.  
Secondly, only women who were screened at the hospital’s mammogram mobile unit at 
five clinics and were found to need further evaluation were included in the study.  Our 
findings may not be generalizable to other settings.  Thirdly, we only used records from 
one hospital to assess patients’ compliance with follow-up.  Although most patients 
receive all of their care at this indigent-care hospital, it is possible that some chose to 
follow-up elsewhere.  Fourth, since staff from the hospital were interviewers and 
respondents were aware of this, participants may have responded to questions in an effort 
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to please interviewers.  Finally, the associations reported here should be interpreted with 
caution, as many of the measures were taken retrospectively, and there is a possibility of 
recall bias.  Additionally, we cannot determine whether responses were a justification for 
actions.  For example, women who did not comply with follow-up may have justified 
their actions by stating that they thought their mammogram results were normal. 
Implications 
 This study adds to the literature on predictors of follow-up after an abnormal 
mammogram.  Although rates of mammography screening have improved among 
women, there may still be barriers of timely performance of subsequent evaluation of 
abnormal mammography.  This is a serious public health concern since breast cancer 
screening can improve breast cancer outcomes only if prompt diagnostic resolution and 
access to state-of-the-art care is available to all screening participants.  For women 
ultimately diagnosed with breast cancer, even short delays in diagnostic resolution may 
be important.   
 The study also contributes to the health disparities literature.  Although previous 
studies regarding factors that influence follow-up are diverse racially and economically, 
this study’s population is primarily low-income minority populations. 
Recommendations 
 It is imperative that medical personnel make a concerted effort to insure that 
patients fully understand mammography results and follow-up instructions.  Improving 
communication of mammogram results and ensuring that the woman with abnormal 
findings fully understands the results and the timing of follow-up may improve 
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compliance with follow-up.  Improving communication during the mammogram process 
and ensuring that the patient is told of next steps may also improve compliance with 
follow-up.  Strategies advocated by health literacy experts, which include asking patients 
to describe their understanding after information is delivered to them, may be helpful.  
Entrance and navigation through the system could be facilitated by a dedicated, 
multidisciplinary staff to evaluate breast disease.  Primary care providers, working more 
closely with surgeons and radiologists, could more effectively communicate concerns, 
discuss results of tests, and establish plans for care.  Urgency must be conveyed to the 
hospital staff about scheduling appointments, diagnostic tests, and procedures so that 
there are minimal wait times.     
 Further research is needed to delineate the relationships between poverty, limited 
health care resources, and provider-patient communications to follow-up care.  
Exploration of the association between incomplete follow-up and future screening 
behaviors, as well as the roles of health literacy and risk perceptions, are important areas 
for in-depth research.  In addition, further qualitative inquiry in this area will not only 
deepen our knowledge about determinants of compliance, but it may also suggest 
avenues of intervention aimed at providing patient-centered quality care and decreasing 
or eliminating disparities in compliance rates.  Ultimately, the benefit of early detection 
will depend on the translation of abnormal screening results into prompt diagnostic and 
treatment services. 
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Conclusions 
 This study identified several factors affecting return for follow-up care after an 
abnormal mammogram.  Because the acceptance and use of mammography is the single 
most effective method of early detection, it is particularly important to understand the 
reasons for delay, as well as inadequate and non-compliance to follow-up care after an 
abnormal mammogram.  We must continue our efforts to educate women to follow 
routine screening recommendations, to recognize breast cancer symptoms earlier, and to 
recognize the benefits of early detection; furthermore, providers must strive to diagnose 
breast cancer as early as possible and target efforts to improve timeliness of care and 
minimize avoidable delays. 
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APPENDIX C 
STUDY INTRODUCTION LETTER 
HIPAA AUTHORIZATION 
INTERVIEW TELEPHONE SCRIPT 
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Study Introduction Letter (English) 
Date 
 
Name 
Address 
City, State, Zip Code 
 
You had a mammogram (breast X-rays) done a little while ago.  We are doing a research 
study to try to find out about some things women could do to stay healthy. We hope that 
you will agree to help us and be a part of our study.  If you agree, please read and sign the 
form, which you will find in the envelope along with this letter.  Then mail it back to us 
in the stamped envelope we sent you.  Once we get your filled-out form someone from 
Parkland will call to ask you a few questions about how things went when you had your 
mammogram and other tests, if you had any.  The call will take about 10 to 15 minutes.  
Any personal information about you will be kept private.  Your name will not be used – 
we will use an ID (identification number) instead.  After we have talked with you we will 
send you a $10 phone card. 
 
If you have any questions, please call Vickie Henry, Project Coordinator at (214) 266-
1240.  Thank you in advance for your help. 
 
Sincerely, 
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Carta de Presentación del Estudio 
 
Fecha 
 
Nombre 
Dirección 
Ciudad, Estado, Código Postal 
 
Hace apenas un tiempo a usted se le hizo un mamograma (rayos X de los senos).  
Nosotros estamos llevando a cabo un estudio de investigación para llegar a saber de 
aquéllas cosas que la mujer pudiera hacer para mantenerse saludable.  Esperamos que 
usted esté de acuerdo en ayudarnos y en participar en nuestro estudio.  Si usted está de 
acuerdo, favor de leer y firmar el formulario, el cual encontrará en el sobre junto con esta 
carta.  Devuelva por correo ésta en el sobre con sello que le enviamos.  Ya cuando 
hayamos recibido su formulario contestado, alguien de Parkland la llamará para hacerle 
unas cuantas preguntas sobre como le fue cuando a usted se le hizo un mamograma y 
otras pruebas, de haberle hecho alguna otra.  La llamada se tomará de unos 10 a 15 
minutos.  Cualquier información personal de usted permanecerá privada.  No se usará su 
nombre — en su lugar usaremos un ID (número de identificación).  Después de haber 
hablado con usted le mandaremos una tarjeta para llamadas telefónicas con un valor de 
$10.00.   
 
Si usted tiene cualquier pregunta, favor de llamar a Vickie Henry, Coordinadora del 
Proyecto al (214) 266-1240.   Le damos por anticipado las gracias por su ayuda. 
 
 
Sinceramente, 
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The University of Texas Southwestern Medical Center at Dallas 
Children’s Medical Center, Parkland Health & Hospital System 
Retina Foundation of the Southwest, Texas Scottish Rite Hospital for Children 
Zale Lipshy University Hospital, St. Paul University Hospital 
The University of Texas Southwestern Moncrief Cancer Center 
 
Authorization for Use and Disclosure of 
Health Information for Research Purposes 
 
NAME OF RESEARCH PARTICIPANT: 
_______________________________________________ 
 
1.   You agree to let Parkland Health & Hospital System share your health 
information with Valerie Copeland and her staff (“Researchers”) for the purpose 
of the following research study: Barriers to Follow-up after an Abnormal 
Mammogram, a study looking at the barriers women encounter when they get a 
mammogram on the Parkland Mammography mobile unit, receive abnormal 
results and have to go to Parkland Health & Hospital System for more exams.    
IRB#__012006-56_ (“Research Project”). 
 
2.  You agree to let the Researchers use your health information for this Research 
Project.   You also agree to let the Researchers share your health information with 
others who may be working with the Researchers on the Research Project 
(“Recipients”) as follows.   
 
• Jeffrey J. Guidry, PhD, Texas A&M University 
 
• The UT Southwestern Institutional Review Board (IRB).  This is a group of 
people who are responsible for assuring that the rights of participants in 
research are respected.  Members and staff of the IRB at UT Southwestern 
may review the records of your participation in this research.  A 
representative of the IRB may contact you for information about your 
experience with this research. If you do not want to answer their 
questions, you may refuse to do so. 
 
• Representatives of the Office of Human Research Protections (OHRP).  
The OHRP may oversee the Research Project to confirm compliance with 
laws, regulations and ethical standards.    
 
3.  Whenever possible your health information will be kept confidential.  Federal 
privacy laws may not apply to some institutions outside of UT Southwestern.    
There is a risk that the Recipients could share your information with others without 
your permission.  UT Southwestern cannot guarantee the confidentiality of your 
health information after it has been shared with the Recipients.   
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4.   You agree to permit the Researchers to use and share your health 
information as listed below:   
Results of mammogram obtained between October 1, 2004 and September 
31, 2005: demographic information(race, age); home telephone contact 
information; survey information obtained during telephone interview. 
  
5.   The Researchers may use your health information to create research data 
that does not identify you.  Research data that does not identify you may be 
used and shared by the Researchers (for example, in a publication about the 
results of the Research Project); it may also be used and shared by the 
Researchers and Recipients for other research purposes not related to the 
Research Project. 
 
6.   This authorization is voluntary.  Your health care providers must continue to 
provide you with health care services even if you choose not to sign this 
authorization.  However, if you choose not to sign this authorization, you cannot 
take part in this Research Project. 
 
7.  This Authorization has no expiration date.  
 
8.   If you change your mind and do not want us to collect or share your health 
information, you may cancel this authorization at any time.  If you decide to 
cancel this authorization, you will no longer be able to take part in the Research 
Project.  The Researchers may still use and share the health information that they 
have already collected before you canceled the authorization.   To cancel this 
authorization, you must make this request in writing to:  [Vickie Henry, 3310 Live 
Oak, Dallas, TX 75235, (214) 266-1240. 
 
9.   A copy of this authorization form will be provided to you. 
 
 
    
Signature of Research Participant    Date 
 
For Legal Representatives of Research Participants (if applicable): 
 
Printed Name of Legal Representative:      
Relationship to Research Participant:  _________________________    
I certify that I have the legal authority under applicable law to make this 
Authorization on behalf of the Research Participant identified above.  The basis 
for this legal authority is: 
______________________________________________________________________________
_________. 
(e.g. parent, legal guardian, person with legal power of attorney, etc.) 
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Signature of Legal Representative  Date 
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The University of Texas Southwestern Medical Center at Dallas 
Children’s Medical Center, Parkland Health & Hospital System 
Retina Foundation of the Southwest, Texas Scottish Rite Hospital for Children 
Zale Lipshy University Hospital, St. Paul University Hospital 
The University of Texas Southwestern Moncrief Cancer Center 
 
Autorización para Usar y Revelar Información sobre Información de Salud 
con Propósitos de Investigación 
NOMBRE DEL PARTICIPANTE EN INVESTIGACIÓN: 
___________________________________________ 
 
1.  Usted está de acuerdo en permitir que el sistema conocido en inglés como 
Parkland Health & Hospital System comparta información sobre su salud con Valerie 
Copeland y su personal (Investigadores) en la Universidad de Texas Southwestern 
Medical Center en Dallas con el propósito de realizar el siguiente estudio de 
investigación:  Obstáculos al Seguimiento luego de un Mamograma Anormal, un estudio 
que examina los obstáculos con los cuales las mujeres se enfrentan cuando obtienen un 
mamograma en la unidad móbil de Mamografías de Parkland (conocido en inglés como 
Parkland Mammography mobile unit), con resultados anormales y tienen que ir a 
Parkland Health & Hospital System para más exámenes. Número del Consejo de 
Revisión Institucional 012006-56 (“Proyecto de Investigación”) 
 
2. Usted está de acuerdo en permitir que los investigadores usen información sobre la 
salud de usted en este Proyecto de Investigación. Usted también está de acuerdo en 
permitir que los investigadores compartan la información de su salud con otras personas 
que pueden estar trabajando con los investigadores en el Proyecto de Investigación 
(“Receptores”) como sigue:  
 
• Jeffrey J. Guidry, PhD, Texas A&M University.  
 
• El Consejo de Revisión Institucional (IRB, por sus siglas en inglés) de UT 
Southwestern. Este es un grupo de personas responsables de asegurar que se 
respetan los derechos de los participantes en investigación. Los miembros o 
personal del IRB en este centro médico pueden revisar los archivos de su 
participación en esta investigación. Un representante del Consejo se podrá 
comunicarse con usted para pedirle información sobre sus experiencias en esta 
investigación. Si usted así lo desea, puede rehusar a contestar sus preguntas. 
 
• Representantes de la Oficina de Protección de Investigación Humana (OHRP, 
por sus siglas en inglés). El OHRP podrá supervisar el Proyecto de 
Investigación para confirmar cumplimiento con las leyes, reglamentos y 
estándares éticos.  
 
3. Siempre que sea posible se mantendrá confidencial la información de su salud. Las 
leyes Federales de Privacidad pueden ser no aplicables a algunas instituciones fuera de 
UT Southwestern . Hay un riesgo de que, sin su permiso, los Receptores puedan 
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compartir información sobre usted con otros. La UT Southwestern no puede garantizar 
la confidencialidad de su información de salud después de que se ha compartido con los 
Receptores. 
4. Usted esta de acuerdo en permitir que los Investigadores usen y compartan 
información sobre su salud como se indica a continuación: Los resultados del 
mamograma que se obtuvieron entre el 1 de octubre del 2004 y el 31 de septiembre del 
2005; información demográfica (raza, edad); información para comunicarse con usted, 
teléfono de la casa; información de la encuesta que se obtuvo por medio de entrevista 
telefónica. 
 
5. Los Investigadores podrán usar la información sobre su salud para crear datos de 
investigación que no lo identifican a usted. Los datos de Investigación que no le 
identifica a usted podrán ser usados y compartidos por los Investigadores (por ejemplo, 
en una publicación sobre el los resultados de este Proyecto de Investigación); podría 
también ser usado y compartido entre los Investigadores y los Receptores para otros 
propósitos de investigación no relacionados con el Proyecto de Investigación. 
 
6.  Esta autorización es voluntaria. Su proveedor de servicios de salud debe continuar 
proporcionándole los servicios de salud aún cuando usted decida no firmar esta 
autorización. Sin embargo, si usted decide no firmar esta autorización, usted no podrá 
participar en el Proyecto de Investigación.   
 
7. Esta autorización no tiene fecha de caducidad.  
 
8. Si usted cambia de opinión y no quiere que nosotros recopilemos y compartamos 
información de su salud, en cualquier momento puede cancelar esta autorización. Si 
usted decide cancelar esta autorización, no podrá participar en el Proyecto de 
Investigación. Los Investigadores podrán usar y compartir la información de salud que 
ya habían recopilado antes de que usted cancelara la autorización. Para cancelar esta 
autorización, usted debe hacer la solicitud por escrito a Vickie Henry, 3310 Live Oak, 
Dallas, TX 75235, (214) 266-1240.   
 
9. Una copia de esta autorización se le proporcionara a usted.  
 
 
    
Firma del Participante en Investigación     Fecha 
 
 
Para Representantes Legales de los Participantes en Investigación (si se aplica): 
 
Nombre en letra de molde del Representante Legal:      
Relación con el Participante en Investigación:  _____________________    
 
Certifico que tengo la autoridad legal bajo las leyes correspondientes para dar esta 
autorización a nombre del Participante en Investigación identificado anteriormente.  Esta 
autoridad legal es a base de:  
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______________________________________________________________________
_________________. 
(e.g. padre o madre, patria potestad, carta poder, etc.) 
    
Firma del Representante Legal   Fecha 
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Telephone Script (English) 
 
Quantitative Analysis of Barriers to Follow-up after an Abnormal Mammogram 
 
Follow-up after an Abnormal Mammogram Questionnaire 
Telephone Script 
 
Hello, I’m __________, calling from Parkland about the mammogram research study.  
About 2 weeks ago, you had gotten a letter about the study, and sent back a form saying 
that you were willing to be a part of the study.  I’d like to ask you some questions about 
things women can do to stay healthy.   
 
My questions will only take about 15 minutes, and, as we told you in the letter, any 
personal information about you will be kept private.  Your name will not be used – we 
will use an ID (identification number) instead.  If there are any questions you don’t want 
to answer, that is OK.  If you choose not to stay in our study that will not change the way 
you are taken care of at Parkland.   
 
If you have any questions about this study, please call the head of the research study, 
Valerie Copeland at (817) 253-8878, or Dr. Jeffrey Guidry at (979) 845-3109. 
 
Texas A&M University and University of Texas, Southwestern Medical School have 
looked over this study, and they have approved it.  If you have any questions about your 
rights when you are part of a research study, you can call Dr. Michael W. Buckley, 
Director of Research Compliance, Office of Vice President for Research at (979) 845-
8585 (mwbuckley@tamu.edu). 
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Guión por Teléfono 
 
Análisis Cuantitativo de los Obtáculos al Seguimiento luego de un Mamograma 
Anormal 
 
Cuestionario sobre el Seguimiento luego de un Mamograma Anormal  
Guión por Teléfono 
 
Hola, me llamo  __________,  y estoy llamando de Parkland en cuanto al estudio de 
investigación sobre el mamograma.  Hace como unas 2 semanas, usted recibió una carta 
sobre el estudio, y usted devolvió un formulario en que indicó que usted estaba dispuesta 
a participar en el estudio.  Me gustaría hacerle algunas preguntas sobre las cosas que las 
mujeres pueden hacer para mantenerse saludable.   
 
Mis preguntas tan sólo tomarán como unos 15 minutos, y, así como se le explicó en la 
carta, cualquier información personal de usted permanecerá privada.  No se usará su 
nombre – en su lugar usaremos un ID (número de identificación).  Si hay alguna pregunta 
que usted no quiere contestar, está bien, no tiene que contestarla.  Si usted decide salirse 
de nuestro estudio eso no cambiará la manera en que usted recibe atención médica en 
Parkland. 
 
Si usted tiene cualquier pregunta sobre este estudio, favor de llamar a la dirigente del 
estudio de investigación, Valerie Copeland al (817) 253-8878, o al Dr. Jeffrey Guidry al 
(979) 845-3109. 
 
La Universidad de Texas A&M y, la Escuela de Medicina Southwestern de la 
Universidad de Texas han examinado este estudio, y éstos lo han aprobado.  Si usted 
tiene cualquier pregunta sobre sus derechos por ser un partícipe en un estudio de 
investigación, puede llamar al Dr. Michael W. Buckley, Director of Research 
Compliance (Oficina de Acatamiento y Cumplimiento en la Investigación), Office of 
Vice President for Research (Oficina del Vice Presidente para Investigación)  al (979) 
845-8585 (mwbuckley@tamu.edu). 
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APPENDIX D 
ENGLISH QUESTIONNAIRE 
SPANISH QUESTIONNAIRE 
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Patient ID :________________________________________ 
 
Last Name _____________________ First Name ________________________ 
 
Telephone Number (_________)  ____________________ 
 
Contact Date ______________________ 
 
Interviewer ____________________________________________ 
 
 
Date  Time  Comments 
 
_________ ________ ______________________________________________ 
 
_________ ________ ______________________________________________ 
 
_________ ________ ______________________________________________ 
 
_________ ________ ______________________________________________ 
 
_________ ________ ______________________________________________ 
 
_________ ________ ______________________________________________ 
 
_________ ________ ______________________________________________ 
 
_________ ________ ______________________________________________ 
 
_________ ________ ______________________________________________ 
 
_________ ________ ______________________________________________ 
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1. How would you describe your general state of health?  Would you say that it is (READ 
RESPONSES) 
 
 1   Excellent              
 2   Good         
 3   Fair OR 
 4   Poor  
 
2. Is there a particular clinic, health center, doctor's office or other place that you usually go to if 
you are sick or need a checkup? 
 
 1   Yes  (skip to question 4)       
 2   No                     
 88   Don’t Know 
 99   Refused 
 
3. What is the main reason you do not have a particular place to go? 
 
 1   Have not needed a doctor       
 2   Previous doctor not available                          
 3   Have not been able to find the right doctor 
 4   Recently moved to the area 
 
4. Do you have any kind of health care coverage, including health insurance, prepaid plans such 
as HMO’s of government plans such as Medicare? 
  
1   Yes            
 2   No               
 
5. Was there a time in the last 12 months when you needed to see a doctor, but could not because 
of the cost? 
 
 1   Yes            
 2   No               
 88   Don’t Know 
 99   Refused 
 
6. Was there a time in the last 12 months when you needed prescribed medications, but could not 
buy them because of the cost? 
 
 1   Yes            
 2   No               
 88   Don’t Know 
99   Refused 
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7. How do you normally get to your doctor appointments? 
 
1. Drive myself         
2. Family member or friend                                                             
3. Taxi 
4. Bus 
5. Walk 
6. Other __________________________________________________________ 
 
BREAST CANCER SCREENINGS 
 
A mammogram is an x-ray of each breast to look for cancer. 
  
8. About how old were you when you had your first mammogram?  
 
 Age_______          
                     
9. How long has it been since you had your last mammogram? 
 Read only if necessary: 
 1   Within the past year (1 to 12 months ago)       
 2   Within the past two years (13 months to 24 months (2 years)             
 3   Within the past three years (25 months to 36 months (3 years) 
 4   Within the past five years (37 months to 5 years ago) 
 5   more than 5 years ago 
 88   Don't know/Not sure 
99   Refused 
 
10. How many mammograms have you had in the last five years? 
 
 Number of mammograms _____       
 2   None                 
 88   Don't know/Not sure 
99   Refused 
 
11. In the past year has a doctor or other health professional recommended that you have a 
mammogram? 
 
1   Yes               
 2   No                          
88   Don't know/Not sure 
99   Refused 
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12. How much did you pay for this mammogram?  Was it NONE, PART, or ALL of the cost? 
  
1. I paid NONE of the cost      
2. I paid PART of the cost                                      
3. I paid ALL of the cost (skip to question 14) 
88   Don't know/Not sure 
99   Refused 
 
13. Which of the following sources paid for (some/all) of the cost of this mammogram? 
 
1. Private insurance        
2. Medicare        
3. Medicaid 
4. Free clinic 
5. Other source ____________________________________________ 
 
14. What was the main reason you had this mammogram? 
 
1. Part of a routine physical exam/screening test     
2. Because of a specific breast problem         
3. First mammogram 
4. Family history  
5. Other ____________________________________________________ 
88    Don't know/Not sure 
99    Refused 
 
15.  Do you know the results of your mammogram? 
 
1   Yes               
 2   No            
88   Don't know/Not sure 
99   Refused 
   
16.  What were the results of this mammogram? 
 
1. Normal          
2. Abnormal/follow-up required        
3. Didn’t remember receiving results 
 
17. After getting your mammogram results, did you receive an appointment for follow-up? 
  
 1   Yes               
 2   No                               
88   Don't know/Not sure 
99   Refused 
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18. Did anyone talk to you about your mammogram results in person?  
 
1   Yes               
 2   No               
88   Don't know/Not sure 
99   Refused 
 
18a. Did anyone talk to you about your mammogram results on the phone?  
 
1   Yes               
 2   No               
88   Don't know/Not sure 
99   Refused 
 
19. Did you understand the explanation of your mammogram results? 
 
1   Yes               
 2   No                       
88   Don't know/Not sure 
99   Refused 
 
20. Did anyone tell you that you would need a more tests? 
 
1   Yes               
 2   No               
88   Don't know/Not sure 
99   Refused 
 
21. Because of these results what additional tests or surgery did you have? 
 
1. None (skip to question 23)       
2. Another mammogram        
3. Ultrasound 
4. Clinical breast exam 
5. Needle biopsy 
6. Tumor/lump removed/ lumpectomy 
7. Breast removed/mastectomy 
 
22. Did the surgery or additional tests indicate that you had cancer? 
 
 1   Yes               
 2   No          
88   Don't know/Not sure 
99   Refused 
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23. Did you have problems with any of the following in getting your follow-up exams? 
 Did you have problems with….(READ RESPONSES) 
 
 Receiving mammogram results     Yes      No      
 Making or receiving a follow-up appointment   Yes No 
The hospital canceling of your follow-up appointment  Yes No     
 Your mammogram results being lost or misplaced  Yes No  
 The hospital rescheduling your follow-up appointment  Yes No 
 Your follow-up appointment being inconvenient for you  Yes No 
 Having to take off work for follow-up appointment  Yes No 
 Not having transportation to follow-up appointment  Yes No 
 Paying for the follow-up exam     Yes No 
 Receiving an unexpected bill for the follow-up exam   Yes No 
 Insurance covering the follow-up exam    Yes No 
Waiting a long time to receive the follow-up appointment    Yes No 
Waiting a long time to be seen by the doctor at the follow-up appointment  Yes No 
 
24. Have you ever had an operation to remove a mass or lump from your breast that was not 
cancer? 
 
1. Yes               
2. No (skip to question 26)                      
3. Lump removed was cancerous 
88   Don't know/Not sure 
99   Refused 
 
25. How many of these operations have you had? 
 
_______          
88   Don't know/Not sure        
99   Refused 
 
26. Has your mother, sisters, or daughters ever had breast cancer? 
 
 1   Yes,  Which relative (mother, sister or daughter) _______________________ 
 2   No               
 88   Don’t Know 
99   Refused 
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A clinical breast exam is when the breasts are felt by a doctor or other health care professional to 
check for lumps or other signs of breast cancer. 
 
27. Have you ever had a clinical breast exam by a doctor or other health professional to check for 
lumps or other signs of breast cancer? 
 
1   Yes            
 2   No     (skip to question 29)                                                             
88   Don't know/Not sure 
99   Refused 
 
28. When did you have your most recent clinical breast exam by a doctor or health care 
professional? 
 
1. Days ago   
2. Weeks ago                                                               
3. Months ago 
4. Years ago 
88   Don't know/Not sure 
99   Refused 
 
Now I would like to ask you about breast self-exams-that is an examination you do yourself 
of your breast for lumps and other possible signs of cancer 
 
29. Do you know how to examine your breast for lumps? 
  
 1   Yes         
 2   No                                                                      
88  Don't know      
99  Refused 
 
30. How often have you examined your breast? 
 
 1   Never          
 2   Once every month                                                                                                                                                 
 3   Once every two months 
 4   Other, please specify _______________________________________ 
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Please tell me if you agree or disagree with the following statements. 
 
31. In spite of advances in modern medicine, breast cancer is as serious and dangerous a disease 
as it was several years ago. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
32. There is a good probability that cancer may now be developing in my breast.  
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
33. I am more vulnerable to breast cancer than anyone else. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
34. The majority of women who develop breast cancer have serious emotional as well as physical 
side-effects. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
35. My chances of developing breast cancer are small. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
36. Having regular mammograms is the best, most effective method of detecting breast cancer 
early. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
37. There are so many ways to get cancer today, its just a matter of time; I might as well just try 
and accept it. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
38. I am currently at risk for developing breast cancer. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
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39. The prospect of developing breast cancer makes me want to have a mammogram every year. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
40. If I have an abnormal mammogram, I can go to the follow-up exams.  
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
41. Having a yearly mammogram will not drastically improve my chances of surviving breast 
cancer. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
42. Only time will tell if I develop breast cancer; nothing can be done anyway but wait. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
43. If I get regular mammograms, my chances of detecting breast cancer are extremely high. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
44. If I have an abnormal mammogram, I believe I can get all the follow-up exams. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
45. If I have an abnormal mammogram, I believe that the cancer will be detected early and I will 
survive. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
46. If you are destined to die of breast cancer, you will; there is really little you can do about it. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
47. Even with advanced medical procedures, the best treatment for cancer involves radical 
surgical techniques. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
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48. Other women are more capable of going to follow-up appointments than I am. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
 
49. Going to follow-up exams are easy to do. 
 
1. strongly 2. disagree 3. neither agree   4. agree  5. strongly  
    disagree       or disagree        agree 
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DEMOGRAPHICS 
 
50. What is your age? 
 
 Age in years _____         
 88   Don't know         
 99   Refused 
 
51. What is the highest grade or year of school you completed? 
 
 1   Never attended school or kindergarten only      
 2   Grades 1 through 8 (Elementary)                                         
 3   Grades 9 through 11 (Some high school) 
 4   Grades 12 or GED (High school graduate) 
 5   College 1 year to 3 years (Some college or technical school) 
 6   College 4 years or more (College graduate) 
 99   Refused 
 
52. Are you: 
 
 1   Married          
 2   Divorced                                                
 3   Widowed 
 4   Separated 
 5   Never been married 
 6   A member of an unmarried couple 
 99   Refused 
 
53.  Are you currently….(READ RESPONSES) 
           
1.    Employed for wages   
2.    Self-employed 
3.    Out of work for more than 1 year 
4.    Out of work for less than 1 year 
5.    A Homemaker 
6.    A Student 
7.    Retired 
99.  Refused  
 
54. Which of the following best describes your annual household income from all sources? 
 
 1   Less than $5,000         
 2   5,000 to 9,999         
 3   10,000 to 19,999 
 4   20,000 to 29,999 
 5   30,000 to 39,999 
 6   40,000 to 49,999 
 7   50,000 and over 
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 88   Don't know 
 99...Refused 
 
That's my last question.  I appreciate you taking the time to complete this important survey.  
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Patient ID :________________________________________ 
 
Last Name _________________________ First Name ________________________ 
 
Telephone Number (_________)  ____________________ 
 
Contact Date ______________________ 
 
Interviewer ____________________________________________ 
 
 
Date  Time  Comments 
 
_________ ________ _______________________________________________ 
 
_________ ________ _______________________________________________ 
 
_________ ________ _______________________________________________ 
 
_________ ________ _______________________________________________ 
 
_________ ________ _______________________________________________ 
 
_________ ________ _______________________________________________ 
 
_________ ________ _______________________________________________ 
 
_________ ________ _______________________________________________ 
 
_________ ________ _______________________________________________ 
 
_________ ________ _______________________________________________ 
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En general, ¿como describiría usted su estado de salud? Diría usted que es (LEA LAS 
RESPUESTAS) 
1. Excelente 
2. Buen estado 
3. Regular O 
4. Pobre 
 
¿Tiene usted en específico, alguna clínica, centro de salud, oficina médica privada o 
algún otro lugar a donde va usted usualmente si está enfermo/a o de necesitar un examen 
de rutina? 
1. Sí (De ser Sí, pase a la pregunta 4) 
2. No 
88 No sé 
99 Rehusa 
 
¿Cuál es la razón principal por la que usted no tiene un lugar en específico a donde ir? 
1. No he necesitado de un doctor 
2. Mi anterior doctor no ha estado disponible 
3. No he podido encontrar un doctor a mi gusto 
4. Recientemente me he mudado al área 
5. Tengo uno o más especialistas quienes tratan mis problemas rutinarios en visitas 
citadas con anticipación (tiene varios doctores de acuerdo a lo que tiene mal) 
6. No hay suficiente dinero/demasiado caro 
7. No me gustan los doctores 
8. No pienso que los doctores me puedan ayudar 
9. Otro:           
88 No sé/No estoy seguro/a 
99 Rehusa 
 
4.      ¿Tiene usted cualquier tipo de cuberturapara el cuidado de la salud, en las se 
incluye, aseguranza de la salud, planes pre-pagados tales como las HMO (siglas en 
inglés) o planes del gobierno tales como Medicare?  
1. Sí 
2. No 
 
5.  ¿Hubo alguna vez en los últimos 12 meses en que usted necesitara de consultar con un 
doctor, pero no pudo hacerlo debido al costo? 
1. Sí 
2. No 
88 No sé  
99 Rehusa 
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6.  ¿Hubo alguna vez en los últimos 12 meses que usted necesitara medicinas por receta, 
pero no pudo hacerlo debido al costo? 
1. Sí 
2. No 
88 No sé  
99 Rehusa 
 
7.  ¿Cómo se transporta usted por lo usual a sus citas? 
 
1. Manejo yo misma 
2. Un miembro de la familia o amigo 
3. Taxi 
4. Autobús 
5. Camino 
6. Otro            
 
PRUEBAS PARA DETECTAR EL CÁNCER DEL SENO 
 
Un mamograma es un rayos X de cada seno para detectar el cáncer.  
 
8.  ¿Qué edad tenía usted más o menos cuando se le hizo el primer mamograma? 
Edad _______ 
 
9.  ¿Cuánto tiempo ha pasado desde que se le hizo el último mamografía? 
Lea si fuera necesario: 
1. En lo que va del último año (1 a 12 meses)  
2. En lo que va de los últimos 2 años (13 a 24 meses) 
3. En lo que va de los últimos 3 años (25 a 36 meses) 
4. En lo que va de los últumos 5 años (37 meses a 5 años) 
5. Más de 5 años 
88 No sé/No estoy seguro/a 
99 Rehusa 
 
10.  ¿Más o menos cuántos mamogramas ha tenido usted en los últimos 5 años? 
1. Número de mamogramas _________ 
2. Ninguno 
88 No sé/No estoy seguro/a 
99 Rehusa 
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11.  ¿En el último año, le ha recomendado el doctor u otro profesional de la salud a usted 
para que se haga un mamograma? 
1. Sí 
2. No 
88 No sé/No estoy seguro/a 
99 Rehusa 
 
12.  ¿Cuanto pagó usted por este mamograma? ¿NADA, SOLO UNA PARTE, o pagó el 
TODO EL COSTO? 
1. No pagué NADA del costo 
2. Pagué UNA PARTE del costo 
3. Pagué TODO el costo (Si ésta es la respuesta dada, pase a la pregunta 14) 
88 No sé/No estoy seguro/a 
99 Rehusa 
 
13.  ¿Cuál de las siguientes fuentes o medios pagó por el costo (en parte/en total) de este 
mamograma? 
1. Aseguranza médica privada 
2. Medicare 
3. Medicaid 
4. Clínica gratuita 
5. Otra fuente ___________________________________________ 
 
14.  ¿Cuál es la razón principal por la que usted se ha hecho este mamograma? 
1. Es parte rutinaria del examen físico/prueba de despistaje 
2. Por un problema específico del seno 
3. Primer mamograma 
4. Historial familiar 
5. Otra fuente        
88  No sé/No estoy seguro/a 
99  Rehusa 
 
15.  ¿Conoce usted los resultados de su mamograma? 
1. Sí 
2. No  
88 No sé/No estoy seguro/a 
99 Rehusa 
 
16.  ¿Cuáles fueron los resultados de su mamograma? 
1. Normal  
2. Abnormal/Se requiere re-evaluación o seguimiento 
3. No recuerdo haber recibido resultados 
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17.   ¿ Después de haber recibido los resultados de su mamograma, le dieron una cita de 
re-evaluación o seguimiento? 
1. Sí 
2. No  
88 No sé/No estoy seguro/a 
99 Rehusa 
 
18.  ¿Alguien le habló sobre los resultados de su mamograma en persona? 
1. Sí 
2. No 
88 No sé/No estoy seguro/a 
99 Rehusa 
 
18a.  ¿Alguien le habló sobre los resultados de su mamograma por teléfono? 
1. Sí 
2. No 
88 No sé/No estoy seguro/a 
99 Rehusa 
 
19.  ¿Entendió usted la explicación que le dieron sobre los resultados de su mamograma? 
 
1. Sí  
2. No 
88 No sé/No estoy seguro/a 
99   Rehusa 
 
20. ¿Se le mencionó a usted por cualquiera de las personas que necesitaría más pruebas?  
  
1. Sí 
2. No  
88 No sé/No estoy seguro/a 
99   Rehusa 
 
21.   Debido a dichos resultados, ¿qué otros exámenes o cirugías se le hicieron? 
1. Ninguno (Si ésta es la respuesta dada, pase a la pregunta 23) 
2. Otro mamograma 
3. Ultrasonido 
4. Examen clínico del seno 
5. Biopsia con aguja 
6. Tumor/extracción de masa/lumpectomía 
7. Quitar el seno/mastectomía 
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22.  ¿Fueron las cirugías u otros exámenes adicionales lo que señalaron que usted tenía 
cáncer? 
1. Sí 
2. No 
      88 No sé/No estoy seguro/a 
99 Rehusa 
 
23.  ¿Tuvo usted algún problema con alguno de los siguientes aspectos para obtener 
exámenes de re-evalución o seguimiento? 
Tuvo usted un problema con.... (LEA LAS RESPUESTAS) 
 
El recibir los resultados del mamograma Sí No 
Dificultad en hacer/recibir citas de re-evalución o seguimiento Sí   No 
Cancelación por parte del hospital de citas de re-evaluación o 
seguimiento  
Sí   No 
Pérdida o extravío de los resultados de su mamograma Sí No 
El hospital le cambia la cita a otra fecha para su re-evalución o 
seguimiento 
Sí   No 
Cita dada de re-evaluación o seguimiento le es inconveniente Sí   No 
Necesita faltar al trabajo para poder asistir a su cita de re-evaluación 
o seguimiento 
Sí No 
Falta de transportación para asistir a su cita Sí   No 
Problema de cubrir el costo de su exámen de seguimiento Sí   No 
Recibir una cuenta inesperada de su examen de re-evaluación o 
seguimiento 
Sí No 
Problema con la cobertura de la aseguranza médica para su examen 
de re-evaluación o seguimiento 
Sí   No 
Se espera mucho tiempo para obtener una cita de re-evaluación o 
seguimiento 
Sí   No 
Se espera mucho tiempo para poder consultar al doctor en su cita de 
re-evaluación o seguimiento 
Sí No 
 
24.  ¿Alguna vez se le ha hecho alguna operación (cirugía) para  extirpar o quitar alguna 
masa o bulto de su seno que no fuera cáncer?   
1. Sí 
2. No (Si ésta es la respuesta dada, pase a la pregunta 26) 
3. La masa removida era cancerosa 
88 No sé/No estoy seguro/a 
99 Rehusa 
 
25.  ¿Cuantas cirugías (operaciones) de este tipo ha tenido usted? 
       
88 No sé/No estoy seguro/a 
99 Rehusa 
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26.  ¿Alguna vez, han tenido cáncer del seno, su madre, hermanas, o hijas? 
1. Sí  Cuál/es (madre, hermanas, hija) _________________ 
2. No 
      88 No sé/No estoy seguro/a 
      99 Rehusa 
 
Un examen clínico de los senos es un examen por tacto de los senos por un doctor u otro 
profesional de salud para detectar masas u otras señales del cáncer del seno. 
 
27.  ¿Alguna vez le ha hecho (un doctor u otro profesional de salud) un examen clínico 
del seno para detectar masas u otras señales del cáncer al seno? 
1. Sí 
2. No (pase a la pregunta 29) 
88 No sé/No estoy seguro/a 
99 Rehusa 
 
28. ¿Cuándo fue su examen clínico de los senos más reciente que le haya hecho un doctor 
o profesional del cuidado de la salud?   
1. Hace algunos días 
2. Hace algunas semanas 
3. Hace algunos meses 
4. Hace algunos años 
88 No sé/No estoy seguro/a 
99 Rehusa 
 
Ahora, me gustaría preguntarle sobre exámenes del seno hechos por usted mismo/a 
— esto es, un examen por tacto de sus senos que usted se hace a sí mismo/a para 
detectar masas/abultamientos y otras posibles señales del cáncer. 
 
29. ¿Sabe usted como examinarse sus senos para detectar masas o abultamientos? 
1. Sí 
2. No 
88 No sé  
99 Rehusa 
 
30. ¿Qué tan a menudo se examina usted los senos? 
 
1. Nunca 
2. Una vez al mes 
3. Una vez cada tres meses 
4. Otro, especifique        
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Favor de decirme si usted está de acuerdo o en desacuerdo con las siguientes 
declaraciones: 
 
31.  A pesar de los avances de la medicina moderna, el cáncer del seno es tan serio y 
peligroso como lo fue hace varios años. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
32.  Hay una buena probabilidad de que el cáncer en estos momentos se esté 
desarrollando en mi seno. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
33.  Yo soy más vulnerable al cáncer del seno que cualquier otra persona. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
34.  La mayoría de las mujeres que desarrollan cáncer del seno tienen efectos secundarios 
serios tanto emocianales como físicos. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
35.  Las probabilidades de desarrollar cáncer del seno son pocas. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
36.  Hacerse mamogramas con regularidad es el mejor método y el más efectivo en la 
detección temprana del cáncer.   
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
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37.  Hay muchas maneras de tener cáncer hoy en día, es una cuestión de tiempo; de una 
vez por todas, debería resignarme y aceptarlo así. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
38.  En estos momentos, corro el riesgo de desarrollar cáncer del seno. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
39.  La posibilidad de desarrollar cáncer causa que quiera hacerme un mamograma cada 
año. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
40.  De tener un mamograma anormal, yo puedo ir a los exámenes de seguimiento.   
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
41.  Hacerme un mamograma cada año no va a mejorar por mucho mis probabilidades de 
sobrevivir cáncer del seno. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
42.  Sólo el tiempo dirá si desarrollo cáncer del seno, no se puede hacer nada, tan sólo 
esperar. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
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43.  Si me hago mamogramas con regularidad, las probabilidades de que detecten cáncer 
son extremadamente altas. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
44.  De tener un mamograma anormal, yo creo que puedo obtener todos los exámenes de 
seguimiento. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
45.  De tener un mamograma anormal, yo tengo fé de que el cáncer se va a detectar a 
tiempo y yo sobreviviré. 
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
46.  Si lo que el destino le guarda a uno es morir de cáncer del seno, así será; en realidad, 
es muy poco lo que usted puede hacer sobre eso.    
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
47. Apesar de los avances en los procedimientos médicos, el mejor tratamiento para el 
cáncer son las técnicas radicales de cirugía.  
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
 
48. Otras mujeres son más hábiles que yo en asistir a las citas de seguimiento.  
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
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49. Es fácil asistir a las citas de seguimiento.  
 
muy en 
desacuerdo 
en desacuerdo ni de acuerdo  
ni en 
desacuerdo 
de acuerdo muy de acuerdo 
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Datos demográficos 
 
50.  ¿Cuántos años tiene usted? 
 
Edad en años      
88 No sé 
99 Rehusa contestar 
 
51.  ¿Cuál es el grado o año más alto de escuela que completó? 
1. Nunca asistí a la escuela o tan sólo jardín de niños 
2. Grados 1 hasta 8 (Primaria) 
3. Grados 9 hasta 11 (Algo de Secundaria) 
4. Grados 12 o GED (Se graduó de la Secundaria) 
5. Universidad 1 año hasta 3 años 
6. Universidad 4 años o más (Graduado de la Universidad o Título Universitario) 
99 Rehusa 
 
52.  Está usted: 
1. Casado/a 
2. Divorciado/a 
3. Viudo/a 
4. Separado/a 
5. Nunca ha estado casado 
6. Un miembro de una pareja no casada 
99 Rehusa 
 
53.  ¿En estos momentos, está usted… (LEA LAS RESPUESTAS) 
1. Trabajando a jornal, a sueldo 
2. Trabajando por cuenta propia, por sí mismo 
3. Sin trabajo por más de un año 
4. Sin trabajo por menos de un año 
5. Ama de Casa 
6. Un/a estudiante 
7. Retirado o Jubilado 
99 Rehusa contestar 
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54.  De las siguientes categorías, ¿cuál describe mejor sus ingresos anuales de la casa de 
todas las fuentes o medios? 
1. Menos de $5,000 
2. 5,000 a 9,999 
3. 10,000 a 19,999 
4. 20,000 a 29,999 
5. 30,000 a 39,999 
6. 40,000 a 49,999 
7. 50,000 y más  
88 No sé  
99 Rehusa 
 
Esa fue mi última pregunta.  Le agradezco el haber tomado de su tiempo para 
completar esta encuesta importante. 
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